Methods, compositions and kits for modifying immune cell activity via KIR2DL5

By reducing KIR2DL5 expression and activity using specific agents, the KIR2DL5/PVR pathway is targeted to enhance NK cell cytotoxicity and antitumor immunity, addressing the unknown functions of KIR2DL5 and overcoming tumor immune evasion.

JP2024542171AInactive Publication Date: 2024-11-13ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024527178
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-08
Filing Date
2022-11-07
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The biological functions of KIR2DL5, a member of the KIR family, are largely unknown, and its interaction with the poliovirus receptor (PVR) contributes to tumor immune evasion, necessitating a therapeutic strategy to target the KIR2DL5/PVR pathway in the tumor microenvironment for improved cancer treatment.

Method used

Methods involving agents that reduce KIR2DL5 expression and/or activity, such as antibodies or small molecules, are administered to modulate immune cell function, preventing KIR2DL5 binding to PVR while allowing other receptors like TIGIT and DNAM-1 to maintain immune cell activity, thereby enhancing immune response against tumors.

Benefits of technology

Blocking KIR2DL5 activity enhances NK cell cytotoxicity and antitumor immunity, leading to reduced tumor growth and improved survival in xenograft models, indicating a potential therapeutic approach for various cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542171000001_ABST
    Figure 2024542171000001_ABST
Patent Text Reader

Abstract

This disclosure provides a method for modifying immune cell activity by altering the expression and / or activity of KIR2DL5, comprising administering to a subject one or more agents that decrease the expression and / or activity of KIR2DL5, thereby increasing immune cell function and treating diseases such as cancer and infectious diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 263,710 (filed November 8, 2021), the disclosure of which is incorporated herein by reference in its entirety.

[0002] Sequence Listing This application contains a sequence listing conforming to ST.26, which was submitted to the Patent Center in xml format and is incorporated herein by reference in its entirety. The xml copy, created on October 28, 2022, has the filename 129807.8027.WO00 Sequence Listing.xml and is 64KB in size. [Background technology]

[0003] Human killer cell immunoglobulin-like receptors (KIRs) regulate the activity of natural killer (NK) cells by recognizing self-HLA class I molecules (Wagtmann 1995; Vilches 2002). KIR2DL5 is a member of the KIR family, but its biological functions are largely unknown (Winter 1998; Frazier 2013; Vilches 2000; Cisneros 2016; Gomez-Lozano 2002; Du 2008).

[0004] Poliovirus receptor (PVR, also known as CD155) is a member of the nectin / nectin-like family that mediates cell adhesion, invasion and migration, and proliferation (Verschueren 2020; Husain 2019; Shilts 2022; Takai 2008; Kucan Brlic 2019). Overexpression of PVR induces immune evasion of tumor cells and is associated with poor prognosis and accelerated tumor progression (Triki 2019; Carlsten 2007; Castriconi 2004; Masson 2001). In addition to its tumor-intrinsic role, PVR is involved in multiple immune regulatory events through interactions with the stimulatory receptor DNAX accessory molecule 1 (DNAM-1, also known as CD226), the inhibitory receptor T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD96 (Bottino 2003; Yu 2009; Chan 2014). Immunotherapies targeting TIGIT / PVR as potential treatments for cancer are in clinical trials (Bendell 2020; Niu 2022; Cohen 2021; Wainberg 2021; Rodriguez-Abreu 2020; Ge 2021). Alternative approaches targeting other PVR pathways may contribute to improved outcomes. Thus, this technology provides a therapeutic strategy targeting the KIR2DL5 / PVR pathway in the tumor microenvironment (TME) to fulfill an urgent need in this field. Summary of the Invention

[0005] This specification provides, in certain aspects, methods of modifying immune cell activity by altering the expression and / or activity of KIR2DL5.

[0006] In one aspect, the disclosure provides a method of increasing immune cell function in a subject, comprising administering to the subject one or more agents that decrease expression and / or activity of KIR2DL5.

[0007] In another aspect, the disclosure provides a method of treating an infectious disease in a subject in need thereof, comprising administering to the subject one or more agents that reduce expression and / or activity of KIR2DL5.

[0008] In yet another aspect, the disclosure provides a method of treating cancer in a subject in need thereof comprising administering one or more agents that reduce the expression and / or activity of KIR2DL5.

[0009] In some embodiments, the one or more agents block or reduce binding of KIR2DL5 to the poliovirus receptor (PVR). In certain of these embodiments, the one or more agents bind to KIR2DL5 at or near its binding site with PVR. In certain of these embodiments, the one or more agents bind to PVR at or near its binding site with KIR2DL5.

[0010] In some embodiments, binding of the one or more agents to PVR does not block binding of PVR to TIGIT, DNAM-1 and CD96.

[0011] In some embodiments, the one or more agents are selected from a peptide, a polypeptide, or a small molecule. In certain of these embodiments, the polypeptide is an antibody or a fusion protein comprising an antibody. In some embodiments, the antibody is a monoclonal antibody. In yet other embodiments, the antibody is an antagonist antibody. In some embodiments, the antibody is a chimeric antibody, a human antibody, or a humanized antibody.

[0012] In some embodiments, the antibody or fusion protein comprising the antibody comprises a high chain variable region (VH) comprising an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, or SEQ ID NO:30.

[0013] In some aspects, the antibody or fusion protein comprising the antibody comprises a VH region comprising an amino acid sequence encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence set forth in SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, or SEQ ID NO:30.

[0014] In some aspects, the antibody or fusion protein comprising the antibody comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27 or SEQ ID NO:31.

[0015] In some aspects, the antibody or fusion protein comprising the antibody comprises a VH region comprising an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27, or SEQ ID NO:31.

[0016] In another aspect, the antibody or fusion protein comprising the antibody comprises a light chain variable region (LH) comprising an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, or SEQ ID NO:32.

[0017] In some aspects, the antibody or fusion protein comprising the antibody comprises an LH region comprising an amino acid sequence encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence set forth in SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28 or SEQ ID NO:32.

[0018] In some aspects, the antibody or fusion protein comprising the antibody comprises an LH region comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29 or SEQ ID NO:33.

[0019] In some aspects, the antibody or fusion protein comprising the antibody comprises an LH region comprising an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29 or SEQ ID NO:33.

[0020] In some embodiments, the infectious disease is caused by a pathogen. In certain of these embodiments, the pathogen is selected from a virus, a bacterium, a prion, a fungus, a parasite, or a combination thereof. In some embodiments, the virus is selected from the group consisting of human immunodeficiency virus, influenza virus, papilloma virus, coronavirus, hepatitis virus, and herpes virus. In some embodiments, the bacterium is Mycobacterium tuberculosis. In some embodiments, the fungus is Pneumocystis jirovecii (PJP).

[0021] In some embodiments, the cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), T-cell lymphoma, B-cell lymphoma, T-cell acute lymphocytic leukemia (T-ALL), chronic myelogenous leukemia (CML), B-cell prolymphocytic leukemia, T-cell lymphoma, Hodgkin's disease, B-cell non-Hodgkin's lymphoma, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell ... The cancer is selected from the group consisting of follicular lymphoma, follicular lymphoma, hairy cell leukemia, small cell follicular lymphoma, large cell follicular lymphoma, malignant lymphoproliferative conditions, mucosa-associated lymphoid tissue (MALT) lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, or preleukemia.

[0022] In yet another aspect, the cancer is selected from the group consisting of colon cancer, rectal cancer, renal cell carcinoma, liver cancer, lung cancer, kidney cancer, stomach cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulva cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, urethral cancer, penile cancer, solid tumors of childhood, bladder cancer, cancer of the kidney or ureter, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal tumors, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, environmentally induced cancer, combinations of cancers, and metastatic lesions of cancer.

[0023] In some embodiments, the cancer is a human hematological malignancy. In certain of these embodiments, the human hematological malignancy is selected from the group consisting of myeloid neoplasms, acute myeloid leukemia (AML), AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML, acute leukemia of unclear lineage, myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, myelofibrosis (MF), primary myelofibrosis, systemic mastocytosis, myelodysplastic syndromes (MDS), myeloproliferative / myelodysplastic disorders, and the like. syndrome, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, myelodysplastic syndromes (MDS), refractory anemia with sideroblasts, refractory cytopenia with polycythemia vera, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), MDS with isolated 5q deletion, unclassifiable MDS, myeloproliferative / myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myelogenous leukemia, juvenile myelomonocytic leukemia, unclassifiable myelodysplastic syndrome Proliferative / myelodysplastic syndromes, lymphoid neoplasms, precursor lymphoid neoplasms, B-lymphoblastic leukemia, B-lymphoblastic lymphoma, T-lymphoblastic leukemia, T-lymphoblastic lymphoma, mature B-cell neoplasms, diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmic

[0023] The present invention is selected from: myeloid leukemia, myeloma, erythropoietin-related lymphoma, erythrocytic lymphoma, erythroblastic lymphoma, pulmonary fibrosis ...

[0024] In some aspects, the cancer is selected from the group consisting of bladder cancer, kidney cancer, breast cancer, lung cancer, liver cancer, brain cancer, prostate cancer, colon cancer, esophageal cancer, pancreatic cancer, uterine cancer, and gastric cancer.

[0025] In some embodiments, the cancer is a metastatic cancer.

[0026] In some embodiments, the methods further comprise administering to the subject one or more additional cancer treatments selected from chemotherapy, radiation therapy, immunotherapy, surgery, and combinations thereof.

[0027] In another aspect, the disclosure provides a method of decreasing immune cell function in a subject, comprising administering to the subject one or more agents that increase expression and / or activity of KIR2DL5.

[0028] In some aspects, the disclosure provides methods of treating an autoimmune disease in a subject, comprising administering to the subject one or more agents that increase expression and / or activity of KIR2DL5.

[0029] In yet another aspect, the disclosure provides a method of reducing transplant rejection in a subject, the method comprising administering to the subject one or more agents that increase expression and / or activity of KIR2DL5.

[0030] In some embodiments, the one or more agents are selected from the group consisting of peptides, polypeptides, and small molecules. In certain of these embodiments, the polypeptide is a fusion protein or an antibody. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is an agonist antibody. In some embodiments, the antibody increases the activity of KIR2DL5. In some embodiments, the antibody is a chimeric antibody, a human antibody, or a humanized antibody.

[0031] In some embodiments, the autoimmune disease is acute disseminated encephalomyelitis (ADEM), alopecia areata, antiphospholipid syndrome, autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disorder, autoimmune lipoproliferative syndrome, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune thrombocytopenic purpura, autoimmune urticaria, autoimmune uveitis, Behcet's disease, celiac disease, Chagas disease, cold agglutinin disease, Crohn's disease, dermatomyositis, 1 type 2 diabetes, eosinophilic fasciitis, gastrointestinal pemphigoid, Goodpasture's syndrome, Graves' syndrome, Guillain-Barre syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, lupus erythematosus, Miller Fisher syndrome, mixed connective tissue disease, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polymyositis, psoriasis, psoriatic arthritis, relapsing polychondritis, rheumatoid arthritis, rheumatic fever, Sjogren's syndrome, temporal arteritis, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease, vasculitis, Wegener's granulomatosis, and adult rheumatoid arthritis.

[0032] In some embodiments, the transplant is a stem cell transplant, a bone marrow transplant, or a combination thereof. In certain of these embodiments, the transplant is selected from the group consisting of a kidney transplant, a lung transplant, a heart transplant, a pancreas transplant, a cornea transplant, or a liver transplant. [Brief description of the drawings]

[0033] [Figure 1] Flow cytometric analysis of PVR binding to KIR2DL5 / 3T3 or KIR2DL4 / 3T3 with increasing concentrations of PVR-Ig. [Diagram 2] Flow cytometric analysis of PVR binding on 3T3 cells expressing wild-type KIR2DL5 and its variants. [Diagram 3] PVR / 3T3 cells were preincubated with the indicated concentrations of CD226-His, CD96-His, TIGIT-His and TMIGD2-His (negative control) tagged proteins and then stained with KIR2DL5-human Ig fusion protein. [Figure 4A-4C](A) FACS analysis of PBMCs shows that KIR2DL5 is expressed on the cell surface of human innate (NK, γδ T cells) and adaptive (CD8+, CD4+ T cells) immune cells. (B) Percentage of KIR2DL5 positive cells on NK cell subsets from eight different donors. (C) Percentage of KIR2DL5+ CD8 T cells on CD8 T cell subsets from eight different donors. [Figure 5A-5D] KIR2DL5 inhibits NK cell function and mediates PVR+ tumor immune resistance. (A-C) Redirected cytotoxicity of primary KIR2DL5+ NK cells against P815. (A) Lysis of P815 cells (n=4). (B) Degranulation (CD107a) and cytokine production (IFN-γ and TNF-α) of primary KIR2DL5+ NK cells (n=4). CD56 is a negative control. (C) Cytokine and chemokine production in the supernatant of co-cultures of primary KIR2DL5+ NK cells with antibody-coated P815 (n=5). (D) Effect of anti-KIR2DL5 blocking mAb F8B30 or control mIgG1 on lysis of scrambled control, or PVRKOA427 or Jurkat cells by primary KIR2DL5+ NK cells at the indicated E:T ratios. [Figures 6A-6F](A-B) A427 subcutaneous tumor model. NSG mice were implanted with A427 sc on day 0, followed by randomization on day 3 and treatment with KIR2DL5+ NK cells with mIgG1 or F8B30 twice every 3 days it. A427 tumor growth (A) and Kaplan-Meier survival curves of mice (B). n=8 tumors per group. (C-D) A427 xenograft lung tumor model. NSG mice were implanted with A427 iv on day 0, followed by randomization on day 1 and treatment with KIR2DL5+ NK cells with mIgG1 or F8B30 twice every 3 days it. Tumor growth in the lungs was monitored by bioluminescence imaging (C) and Kaplan-Meier survival curves of mice (D). n=5 mice per group. (E-F) Jurkat xenograft tumor model. NSG mice were implanted iv with Jurkat on day 0, then randomized on day 4 and treated iv with KIR2DL5+ NK cells with mIgG1 or F8B30 twice every 3 days. Tumor growth was monitored in vivo by bioluminescence imaging (E) and Kaplan-Meier survival curves of mice (F). n=6 mice per group. [Figure 7A-7B] (A) Expression and phosphorylation of Vav1, ERK1 / 2, p90RSK and NF-κB in primary KIR2DL5+ NK cells after cross-linking with the indicated mAbs at the indicated time points. (B) Quantitation of immunoblotting. [Figure 8A-8D]Preparation and characterization of anti-KIR2DL5 specific mAbs. (A) Specificity of anti-KIR2DL5 mAb clone F8B30. 3T3 cells transduced with the indicated KIR family were stained with 5 μg / mL of F8B30 (open) or mIgG1 (shaded). (B) 3T3 cells transduced with D0-deficient (KIR2DL5 dD0) or D2-deficient KIR2DL5 (KIR2DL5 dD2) were stained with 5 μg / mL of clone F8B30 or commercial clone UP-R1. (C) Anti-KIR2DL5 mAb clone F8B30 recognized different KIR2DL5A and 5B alleles. 3T3 cells transduced with the indicated alleles were stained with 5 μg / mL of F8B30 or UP-R1 (open) or mIgG1 (shaded). (D) Anti-KIR2DL5 mAb clone F8B30 recognized different KIR2DL5 D0 domain variants. 3T3 cells transduced with the D0 variants were stained with 0.025 μg / mL of F8B30 or UP-R1 (open) or mIgG1 (shaded). (A-D) Data are from two independent experiments. [Figure 9A-9F]KIR2DL5 was expressed on human innate and adaptive immune cells. (A) KIR2DL5 expression on human PBMC. Frequency of KIR2DL5+ cells in the indicated subsets (n=17 for NK and CD8+ T; n=15 for CD4+ T and γδT). Data are presented as mean ± SEM. Figure 4A (see above) shows flow cytometry analysis of KIR2DL5 expression on the indicated subsets from one donor. (B) Distribution of KIR2DL5+CD8+ T cells on the indicated cell subsets based on CD45RA and CCR7 expression. Figure 4C (see above) summarizes the KIR2DL5+CD8+ T cell distribution (n=8). Data are presented as mean ± SEM. (C) KIR2DL5 expression on CD56brightCD16- and CD56dimCD16+ NK subsets. The frequency of KIR2DL5+ cells on the indicated NK cell subsets is shown in Figure 4B (n=8) (see above). (D) KIR2DL5 expression on CD56dimCD57- and CD56dimCD57+ NK subsets. The frequency of KIR2DL5+ cells on the indicated NK cell subsets (n=8) is shown on the right. (E) Flow cytometric analysis of the co-expression pattern of KIR2DL5 with DNAM-1, TIGIT and CD96 on primary resting or IL-2+IL-15 activated NK cells. (F) Co-expression pattern of KIR2DL5 with other receptors on NK cells derived from human PBMC. t-SNE plots were generated based on spectral flow cytometry data (n=3). (E) Data are from three independent experiments with three different donors. P values ​​were determined by one-way ANOVA (A and B) or paired two-tailed t-test (C and D). [Figure 10A-10E]Allelic polymorphism affected PVR binding of KIR2DL5. (A) Flow cytometric analysis of PVR-Ig or CD112-Ig (open) or control hIg (shaded) binding to KIR2DL5 / 3T3. (B) Flow cytometric analysis of PVR-Ig binding to KIR2DL5 / 3T3 in the presence of increasing concentrations of F8B30. (C) KIR2DL5 bound to a site on PVR that is distinct from other receptors. PVR-Ig protein was preincubated with His-tagged proteins and then stained with KIR2DL5 / 3T3 cells. Figure 3 (see above) shows that PVR / 3T3 cells were preincubated with the indicated concentrations of DNAM-1-His, CD96-His, TIGIT-His or TMIGD2-His (negative control) tagged proteins and then stained with KIR2DL5-Ig fusion protein. (D) Flow cytometric analysis of PVR-Ig (open) or control hIg (shaded) binding on 3T3 cells expressing WT, D0-null or D2-null KIR2DL5. Parental 3T3 cells were used as negative control. (E) Flow cytometric analysis of PVR-Ig or control hIg (shaded) binding on 3T3 cells expressing different KIR2DL5 alleles. (A-E) Data from two independent experiments. [Figure 11A-11B]KIR2DL5 inhibited NK cell function and mediated PVR+ tumor immune resistance. (A) PVR-KIR2DL5-mediated inhibitory synapse formation. Left: Representative images of cell conjugates obtained upon contacting sorted KIR2DL5+ primary NKs with control-YFP / Raji (top) or PVR-YFP / Raji (bottom) followed by staining with anti-KIR2DL5 mAb and phalloidin. Scale bar: 10 μm. Right: Quantification of F-actin, YFP and KIR2DL5 intensity at the immune synapse (IS) and far-synapse (non-IS) cell surface from KIR2DL5+ NK cell-control Raji (n=25) and KIR2DL5+NK-PVR / Raji (n=35) conjugates. (B) Lysis of scrambled control or PVRKOA427 (top) or Jurkat (bottom) cells by sorted KIR2DL5+ primary NK cells in the presence of F8B30 or mIgG1 at the indicated E / T ratios. (B) Data are means of duplicate determinations and three independent experiments performed with three different donors. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by two-tailed paired Student's t test (A) or unpaired multiple t test (B). [Fig. 12A-12E]KIR2DL5 ITIMs and ITSMs mediated NK cell inhibition and suppressed signaling. (A) Tyrosine (Y) in the ITIMs and ITSMs of KIR2DL5 was mutated to phenylalanine (F). KIR2DL5- primary NK cells were transduced with WT KIR2DL5 or the indicated mutants and then probed for protein expression using F8B30 (open) or mIgG1 (shaded). NC, negative control. Data are from two independent experiments. (B and C) Transduced primary NK cells were treated with (+) or without (-) pervanadate (VO4) for 5 min. Cell lysates were immunoprecipitated with anti-KIR2DL5 antibody. Phosphotyrosine (4G10), SHP-1, SHP-2 and total KIR2DL5 were detected by immunoblotting (B). Quantification of p-Tyr, SHP-1 and SHP-2 association with WT or mutant KIR2DL5 in VO4-treated NK cells (C). WCL, whole cell lysate. (D) Representative images of cell conjugates obtained upon contact of the indicated transduced primary NK and PVR / Raji cells followed by staining with anti-KIR2DL5 mAb and DAPI. Scale bar: 10 μm. (E) Lysis of scrambled control or PVRKOA427 (top) or Jurkat (bottom) by the indicated E / T ratios of WT or mutant KIR2DL5-transduced primary NK cells. Data are means for duplicate determinations and from three independent experiments with three different donors. (A-B) Data from three independent experiments. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA (C) or paired Student's t-test (D). [Figure 13] KIR2DL5+ immune cells infiltrated a variety of human PVR+ cancers. Representative images of co-expression of KIR2DL5 and CD45 mRNA detected by RNAScope™ (left) and PVR protein expression detected by IHC (right) in the indicated cancers. The top right gate of the RNAScope™ images shows co-expression of KIR2DL5 (green) and CD45 (red) mRNA in the indicated human cancers. Scale bars: 50 μm for RNAScope™ images, 200 μm for IHC images. [Fig. 14A-14H]Blockade of KIR2DL5 promotes NK-based antitumor immunity. (A-B) Blockade of KIR2DL5 enhanced NK cell function in vitro. Selected primary KIR2DL5+ NK cells preincubated with mIgG1 or F8B30 were co-cultured with A427 (A) or Jurkat (B) tumor cells at 2:1 and 5:1 E / T, respectively. Tumor cell lysis as well as degranulation (CD107a) and cytokine production (IFN-γ and TNF-γ) of NK cells from different donors (n=6 for A427, n=4 for Jurkat) are shown. (C) Lysis of A427 and K562 cells by selected primary KIR2DL5+ NK cells in the presence of the indicated mAbs at the indicated E / T ratios. Data are the mean of duplicates, 3 independent experiments with 3 different donors. (D) Subcutaneous A427 tumor model with sorted primary KIR2DL5+ NK cells. (D) Schematic of experimental design. A427 tumor growth. n=8 tumors per group (Fig. 6A, see above). Kaplan-Meier survival curves of mice (Fig. 6B, see above). (E-F) A427 lung metastasis model with sorted primary KIR2DL5+ NK cells. (E) Schematic of experimental design. (F and Fig. 6C, see above) Tumor growth was monitored by bioluminescence imaging. n=5 mice per group. Kaplan-Meier survival curves of mice (Fig. 6D, see above). (G-H) Jurkat metastasis model with sorted primary KIR2DL5+ NK cells. (G) Schematic of experimental design. (L and Fig. 6E, see above) Tumor growth was monitored by bioluminescence imaging. n=6 mice per group. Kaplan-Meier survival curves for mice (Figure 6F, see above). (D), (E), and (G), Data are from two independent experiments. P values ​​determined by paired two-tailed Student's t-test (A–B). [Figures 15A-15E]Characterization of anti-KIR2DL5 specific monoclonal antibodies. (Related Figures 8A-8D). (A) Protein sequence of KIR2DL5. The extracellular domain of KIR2DL5 was composed of tandem D0-D2 domains. The cytoplasmic tail of KIR2DL5 contained immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-dependent switch motifs (ITSMs). Domains were predicted and annotated based on UniProtKB (Q8N109). (B) Specificity of anti-KIR2DL5 mAbs. 3T3 cells transduced with the indicated KIR families were stained with 5 μg / ml of the indicated KIR2DL5 mAbs (open) or mIgG1 (shaded). (C, D) Affinities of anti-KIR2DL5 mAbs. C: Kinetic binding curves for F8B30 and B19C11. D: Data were obtained from kinetic binding curves detected with an Octet Red96BLI instrument for the indicated clones. (E) 3T3 cells transduced with D0-deficient (KIR2DL5 dD0) or D2-deficient KIR2DL5 (KIR2DL5 dD2) were stained with 5 μg / ml of the indicated anti-KIR2DL5 mAb. (B–E) Data are from three independent experiments. [Figure 16A-16B] Allelic polymorphism influenced mAb recognition of KIR2DL5. (Related Figures 8A-8D). (A) Binding of anti-KIR2DL5 mAb (5 μg / ml, open) and mIgG1 (shaded) to 3T3 cells expressing different KIR2DL5A and KIR2DL5B alleles. (B) Binding of anti-KIR2DL5 mAb (5 μg / ml, open) and mIgG1 (shaded) to 3T3 cells expressing different KIR2DL5 D0 variants. (A-B) Data from two independent experiments. [Figure 17A-17B]KIR2DL5 was expressed primarily on mature NK cells. (Related Figures 9A-9F). (A) Gating strategy for immune cell subsets in human PBMCs. (a) Primary lymphocytes were gated based on FCS-A and SSC-A; (b) Doublets were excluded by plotting SSC-H / SSC-A. (c) Live CD19- cells were gated from single cells based on CD19 and live / dead blue staining; (d) CD3-CD56+ cells were defined as NK cells; (e) From CD3+CD56- cells, γδT were defined based on TCRγ / δ staining; (f) CD3+TCRγ / δ- cells were divided into CD4+T and D8+T subsets. (B) KIR2DL5A expression in human normal hematopoietic cells. A hierarchical differentiation tree was generated from the BloodSpot database (https: / / servers.binf.ku.dk / bloodspot / ?gene=KIR2DL5A&dataset=DMAP). [Figures 18A-18C] Characterization of KIR2DL5 as a binding partner for PVR. (Related Figures 10A-10F). (A) Flow cytometric analysis of PVR binding to KIR2DL5 / 3T3 or KIR2DL4 / 3T3 with increasing concentrations of PVR-Ig. (B) KIR2DL5-PVR interaction by cell-cell conjugation assay. Left: Pre-labeled KIR2DL5 / 3T3 and PVR / 3T3 cells were incubated simultaneously and then analyzed by flow cytometry. Co-incubation of KIR3DL3 / 3T3+HHLA2 / 3T3 and KIR3DL3 / 3T3+PVR / 3T3 were used as positive and negative controls, respectively. Right: Summary of cell-cell conjugation for the indicated groups. Data are means ± SEM from three independent experiments. P values ​​by one-way ANOVA. (C) Cell-cell conjugation assay between KIR2DL5 / 3T3 and PVR / 3T3 in the presence of the indicated anti-KIR2LD5 mAbs. Co-incubation of KIR3DL3 / 3T3+PVR / 3T3 served as a negative control. (A and C) Data from three independent experiments. [Figures 19A-19J]KIR2DL5 mediated PVR+ tumor immune resistance to NK cytotoxicity (related Figs. 5A-5D and 11A-11B). (A) KIR2DL5+ primary NK cells were sorted from human PBMCs and cultured in vitro. Expression of KIR2DL5 was confirmed by flow cytometry using F8B30 (open) or mIgG1 (shaded). (B) Expression of other immune receptors on KIR2DL5+ primary NK cells in A. Data are presented as mean ± SEM from six different donors. (C) Primary NK cells were transduced with empty vector (control NK) or KIR2DL5 (KIR2DL5 / NK) and KIR2DL5 expression was examined using F8B30 (open) or mIgG1 (shaded). (D, E) Expression of activating or inhibitory ligands on A427 (D) and Jurkat (E). Cells were stained with the indicated markers (open) and isotype control (shaded). (F-H) Scrambled control and PVRKOA427 (F), Jurkat (G) and K562 (H) cell lines were prepared and examined for PVR expression using anti-PVR mAb (open) or isotype control (shaded). (I) Lysis of scrambled control or PVRKOK562 cells by KIR2DL5+ primary NK cells or control KIR2DL5- NK cells at the indicated E:T ratios. Data are means of duplicate determinations and from three independent experiments with three different donors. (J) Control Raji and PVR / Raji cell lines were prepared and examined for PVR expression using anti-PVR mAb (open) or isotype control (shaded). (A, C-H and J) Data are from three independent experiments. P values ​​from unpaired multiple t-test (I). **P<0.01, ****P<0.0001; ns, not significant. [Figure 20A-20B]The ERK1 / 2 / p90RSK pathway was involved in KIR2DL5 signaling. (Related Figures 7A-7B and 12A-12E). (A, B) Human phospho-kinase array of KIR2DL5+ primary NK cells after 2 min cross-linking with anti-CD16 and mIgG1 (CD16 only), or anti-KIR2DL5 mAb F8B30 (CD16+KIR2DL5). (A) Kinase spots with significantly different densities between the two groups are shown. (B) Relative quantification of phosphorylation levels of the indicated kinases. Data are from two independent experiments. [Figures 21A-21C] KIR2DL5 was upregulated in solid and hematopoietic tumors. (Related Figure 13). (A) mRNA expression of KIR2DL5, TIGIT, CD96, and DNAM-1 in human tumors and corresponding normal tissues by analyzing the indicated Gene Expression Omnibus (GEO) database. (Breast cancer, n=43 vs. 7; ATLL (Adult T-cell leukemia / lymphoma, n=12 vs. 10; MCC (Merkel cell carcinoma), n=27 vs. 64 (number of human tumors vs. normal tissues)). Data are mean ± SEM. (B) Analysis of KIR2DL5A mRNA expression in primary human AML (acute myeloid leukemia) compared to normal hematopoietic cells across cytogenetic subtypes. Hierarchical differentiation trees were generated from the BloodSpot database (https: / / servers.binf.ku.dk / bloodspot / ?gene=KIR2DL5A&dataset=MERGED_AMLL). (C) Representative RNAScope™ images of KIR2DL5 staining positively on a KIR2DL5+ primary NK cell slide mixed with A427 and negatively on a KIR2DL5- human PBMC slide. Scale bar, 10 μm. [Fig. 22A-22E]Blocking KIR2DL5 promotes NK-based anti-tumor immunity. (Related Figures 6A-6F and 14A-14H). (A) Tumor lysis and NK degranulation after co-culture of IL-2+IL-15 stimulated primary NK cells with A427 cells in the presence of anti-TIGIT mAb or isotype control. (B) Degranulation of KIR2DL5+ primary NK cells after co-culture with A427 or K562 cells in the presence of the indicated mAbs at E:T=2:1. (C-E) A427 subcutaneous tumor model in NSG-hIL15 mice. (C) Schematic of experimental design. NSG-hIL-15 mice were implanted sc with A427 (3x106 / mouse) on day 0, followed by randomization on day 5 to receive it treatment twice every 3 days with KIR2DL5+ primary NK cells with mIgG1 or F8B30. (D) A427 tumor growth. n=6 tumors per group. (E) Tumor weights and images for each group on day 23. (A-B) Data are means ± SEM from three independent experiments with three or four different donors. P values ​​by unpaired two-tailed Student's t test (A, E), one-way ANOVA (B), two-way ANOVA (D). sc, subcutaneous; it, tumor. ns, not significant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] Detailed Description The following description is intended to merely illustrate various aspects of the present invention. Therefore, the specific modifications discussed should not be construed as limitations on the scope of the invention. It is apparent to those skilled in the art that various equivalents can be made, changed, and modified without departing from the scope of the invention, and such equivalent aspects are understood to be included in this specification.

[0035] The natural killer cell protein KIR2DL5 is a type I transmembrane molecule that contains an N-terminal signal peptide, an ectodomain composed of tandem D0-D2 domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-dependent inhibitory motifs (ITIMs) and immunoreceptor tyrosine-dependent switch motifs (ITSMs). The amino acid sequence of KIR2DL5 is shown in SEQ ID NO:1.

[0036] SEQ ID NO: 1: MSLMVISMACVGFFLLQGAWTHEGGQDKPLLSAWPSAVVPRGGHVTLLCRSRLGFTIFSLYKEDGVPVPELYNKIFWKSILMGPVTPAHAGTYRCRGSHPRSPIEWSAPSNPLVIVVTGLFGKPSLSAQPGPTVRTGENVTLSCSSRSSFDMYHLSREGRAHEPRLPAVPSVNGTFQADFPLGPATHGGTYTCFGSLHDSPYEWSDPLLVSVTGNSSSSSSSPTEPSSKTGIRRHLHILIGTS VAIILFIILFFFLLHCCCSNKKNAAVMDQEPAGDRTVNREDSDDQDPQEVTYAQLDHCVFTQTKITSPSQRPKTPPTDTTMYMELPNAKPRSLSPAHKHHSQALRGSSRETTALSQNRVASSHVPAAGI (1-21: signal peptide; 22-239: extracellular domain; 42-102: D0; 137-200: D2; 240-259: transmembrane domain; 260-374: cytoplasmic tail; 296-301: ITIM; 326-331: ITSM; see also NP_065396.1).

[0037] The NCBI accession number and Ensembl gene number of KIR2DL5 are NG_005994.1 (NM_020535.3, NP_065396.1) and ENSG00000274143.1, respectively. The NCBI accession numbers and Ensembl gene numbers provided in this specification were accessed on October 28, 2022.

[0038] KIR2DL5 was recently identified as a binding partner of the poliovirus receptor (PVR) by a high-throughput in vitro screen of the IgG superfamily (IgSF) (Husain 2019; Wojtowicz 2020), but the biology of the KIR2DL5-PVR pathway is largely unknown (Beziat 2017).

[0039] As disclosed herein, KIR2DL5 is an inhibitory receptor of the immune system. Specifically, it has been found that (1) KIR2DL5 and the PVR receptors TIGIT, DNAM-1, and CD96 can simultaneously bind to non-identical sites on PVR; (2) KIR2DL5 is expressed on the surface of human adaptive and innate immune cells; (3) KIR2DL5 inhibits NK cell function and mediates PVR+tumor immune resistance; and (5) blocking KIR2DL5 promotes anti-tumor immunity. Based on these results, this specification provides methods and compositions for increasing immune cell activity by inhibiting KIR2DL5 expression and / or activity, and decreasing immune cell activity by increasing KIR2DL5 expression and / or activity.

[0040] KIR2DL5 is polymorphic, 2DL5A * 001 and 2DL5A * 005 (Cisneros 2016). Most KIR2DL5B alleles are epigenetically silent due to a unique substitution in the promoter RUNX binding site, but there are some KIR2DL5B alleles that have an intact RUNX binding site. * 003 and 2DL5B * The 00602 allele is predicted to be transcribed and expressed on the cell surface (Du 2008). These two alleles are the KIR2DL5A allele, which is the allele that F8B30 uses to recognize KIR2DL5. * It has an identical D0 domain to 001 and only four polymorphic sites: T46S, R52H, G97S and P112S (IPD-KIR database, release 2.9.0) (Robinson 2010).

[0041] definition As used herein, the terms "treat," "treating," and "treatment" in reference to a medical condition refer to partially or completely alleviating the condition; slowing the progression or onset of the condition; eliminating, reducing, or delaying the onset of one or more symptoms associated with the condition; or increasing the time to progression or overall survival of the condition.

[0042] As used herein, the terms "prevent, preventing, prevention" as used with respect to a medical condition refer to avoiding the onset of a medical condition or reducing the likelihood of the occurrence or recurrence of a medical condition, including a medical condition in a subject who is susceptible to, but has not yet been diagnosed with, such a condition.

[0043] The term "infectious disease" may refer to a disease caused by an infectious organism, such as a virus, a bacterium, a parasite, and / or a fungus.

[0044] As used herein, the term "antibody" refers to an immunoglobulin molecule or immunologically active portion thereof that binds to a specific antigen, e.g., a cancer cell antigen, a viral antigen, or a microbial antigen. In embodiments where the targeting moiety is an antibody and the antibody is a full-length immunoglobulin molecule, the antibody comprises two heavy chains and two light chains, each of which has three complementarity determining regions (CDRs). In embodiments where the targeting moiety is an antibody and the antibody is an immunologically active portion of an immunoglobulin molecule, the antibody can be, for example, a Fab, Fab', Fv, F(ab')2, a disulfide-linked Fv, scFv, a single domain antibody (dAb), a diabody, a triabody, a tetrabody, or a linear antibody. The antibody used as the targeting moiety can be, for example, a natural antibody, a synthetic antibody, a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a multispecific antibody, a bispecific antibody, a bispecific antibody, an anti-idiotypic antibody, or a fragment thereof that retains the ability to bind to a specific antigen.

[0045] As used herein, a "subject" refers to a mammal, preferably a human.

[0046] Based on the results disclosed herein showing that KIR2DL5 inhibits human immune cell function, in certain embodiments, this specification provides a method of increasing human immune cell function in a subject by decreasing KIR2DL5 expression and / or activity. Further provided is a method of treating infectious disease in a subject by decreasing KIR2DL5 expression and / or activity, since increasing immune cell function can increase pathogen recognition and elimination. Similarly, provided is a method of treating cancer in a subject by decreasing KIR2DL5 expression and / or activity, since increasing immune cell function can increase cancer cell killing.

[0047] In certain embodiments of the methods described herein, the activity of KIR2DL5 is decreased in a subject by administering one or more agents that block or reduce binding of KIR2DL5 to PVR. In certain of these embodiments, the agents bind to KIR2DL5 and block or reduce the binding interaction with PVR, e.g., by binding to KIR2DL5 at or near the binding site with PVR. In other embodiments, the agents bind to PVR and block or reduce the binding interaction with KIR2DL5, e.g., by binding to PVR at or near the binding site with KIR2DL5. In certain embodiments, agents that decrease the activity of KIR2DL5 by binding to PVR and blocking or reducing KIR2DL5 / PVR binding also prevent binding of PVR to one or more other known receptors, including TIGIT, DNAM-1, and CD96. In other embodiments, agents block or reduce binding of KIR2DL5 to PVR, allowing PVR to bind to one or more other known receptors. In certain aspects of the methods described herein, the agent that blocks or reduces binding of KIR2DL5 to PVR is a peptide, polypeptide, or small molecule. Suitable polypeptides include, but are not limited to, antibodies that specifically bind to KIR2DL5 or PVR, truncations of KIR2DL5 or PVR (e.g., the extracellular domain of KIR2DL5 or PVR or a portion thereof), and fusion polypeptides comprising an antibody or truncation of KIR2DL5 or PVR.

[0048] In certain embodiments of the methods described herein, KIR2DL5 activity and / or expression is decreased in a subject by administering one or more agents that inhibit one or more pathways that upregulate KIR2DL5 expression. This inhibition can occur at any step in the pathway, for example, by inhibiting the interaction of a surface receptor with its ligand, inhibiting the interaction of two or more proteins within a cell, blocking the promoter region of KIR2DL5, etc.

[0049] In certain embodiments of the methods described herein, the activity and / or expression of KIR2DL5 is decreased in a subject by altering the sequence of the KIR2DL5 gene or one or more of its corresponding regulatory domains (e.g., promoter, enhancer). For example, in certain embodiments, a CRISPR / Cas (e.g., CRISPR / Cas9) system may be used to introduce one or more nucleotide substitutions, insertions, or deletions into the KIR2DL5 gene or its corresponding regulatory domains.

[0050] In some embodiments, methods are provided for treating an infectious disease in a subject in need thereof by reducing KIR2DL5 expression and / or activity as disclosed herein. In certain of these embodiments, the infectious disease is caused by a pathogen. The pathogen may be one or more of a virus, a bacterium, a prion, a fungus, and a parasite. In some embodiments, the virus is selected from the group consisting of human immunodeficiency virus, influenza virus, papilloma virus, coronavirus, hepatitis virus, or herpes virus. In some embodiments, the bacterium is Mycobacterium tuberculosis. In certain embodiments, the fungus is Pneumocystis jirovecii (PJP).

[0051] In some embodiments, methods are provided for treating cancer in a subject in need thereof by reducing KIR2DL5 expression and / or activity as disclosed herein. In certain of these embodiments, the cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), T-cell lymphoma, B-cell lymphoma, T-cell acute lymphocytic leukemia (T-ALL), chronic myelogenous leukemia (CML), B-cell prolymphocytic leukemia, T-cell lymphoma, Hodgkin's disease, B-cell non-Hodgkin's lymphoma, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large intestine ... In one embodiment, the cancer is selected from the group consisting of malignant large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell follicular lymphoma, large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, or preleukemia. In other aspects, the cancer is selected from the group consisting of colon cancer, rectal cancer, renal cell carcinoma, liver cancer, lung cancer, cancer of the small intestine, cancer of the esophagus, melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, cancer of the vulva, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, urethral cancer, penile cancer, solid tumors of childhood, bladder cancer, cancer of the kidney or ureter, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal tumors, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, environmentally induced cancer, combinations of cancers, and metastatic lesions of cancer. In other aspects, the cancer is a hematological malignancy in humans.

[0052] In certain embodiments, the human hematological malignancy is selected from the group consisting of myeloid neoplasms, acute myeloid leukemia (AML), AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML, acute leukemia of unclear lineage, myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, myelofibrosis (MF), primary myelofibrosis, systemic mastocytosis, myelodysplastic syndromes (MDS), myeloproliferative / myelodysplastic syndromes, chronic my ... Myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, myelodysplastic syndromes (MDS), refractory anemia with sideroblasts, refractory cytopenia with polycythemia dysplasia, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), MDS with isolated 5q deletion, unclassifiable MDS, myeloproliferative / myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myelogenous leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome, lymphoid neoplasm, precursor lymphoid neoplasm, B-lymphoblastic leukemia, B-lymphoblastic lymphoma, T-lymphoblastic leukemia, T-lymphoblastic lymphoma, mature B-cell neoplasm, diffuse large B-cell lymphoma, primary central nervous system lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmocytic lymphoma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disease, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, or solitary plasmacytoma (bone and extramedullary).

[0053] In certain embodiments of the methods described herein, the agent that decreases the activity and / or expression of KIR2DL5 is an antibody that specifically binds to KIR2DL5, an immunogenic fragment thereof or an antibody fragment thereof, or a fusion protein comprising such an antibody. In certain of these embodiments, the antibody is a monoclonal antibody. In certain embodiments, the antibody is a chimeric antibody, a humanized antibody, or a fully human antibody.

[0054] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a variable heavy chain (VH) sequence that includes one or more of the sequences of the CDRs of antibody B2A18 disclosed herein, i.e., the sequences of residues 45-54, 69-85, and 116-131 of SEQ ID NO: 3. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of the amino acid sequence set forth in SEQ ID NO: 3, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 3. In certain aspects, the VH chain is encoded by the nucleic acid sequence set forth in SEQ ID NO: 2, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 2.

[0055] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a variable light chain (VL) sequence that includes one or more of the sequences of the CDRs of antibody B2A18 disclosed herein, i.e., the sequences of residues 24-32, 50-56, and 89-97 of SEQ ID NO: 5. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 5, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 5. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 4, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 4.

[0056] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:3, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:3, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:5, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:5.

[0057] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VH chain sequence that includes one or more of the sequences of the CDRs of antibody B7B23 disclosed herein, i.e., the sequences of residues 45-54, 69-85, and 116-125 of SEQ ID NO: 7. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 7, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 7. In certain aspects, the VH chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 6, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 6.

[0058] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VL chain sequence that includes one or more of the sequences of the CDRs of antibody B7B23 disclosed herein, i.e., the sequences of residues 47-63, 79-85, and 118-126 of SEQ ID NO: 9. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 9, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 9. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 8, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 8.

[0059] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:7, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:7, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:9, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:9.

[0060] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VH chain sequence that includes one or more of the sequences of the CDRs of antibody B11B4 disclosed herein, i.e., the sequences of residues 45-54, 69-87, and 116-127 of SEQ ID NO: 11. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of the amino acid sequence set forth in SEQ ID NO: 11, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 11. In certain aspects, the VH chain is encoded by the nucleic acid sequence set forth in SEQ ID NO: 10, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 10.

[0061] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VL chain sequence that includes one or more of the sequences of the CDRs of antibody B11B4 disclosed herein, i.e., the sequences of residues 46-60, 76-82, and 115-123 of SEQ ID NO: 13. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 13, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 13. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 12, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 12.

[0062] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:11, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:11, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:13, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:13.

[0063] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VH chain sequence that includes one or more of the sequences of the CDRs of antibody B19C11 disclosed herein, i.e., the sequences of residues 44-54, 69-84, and 115-129 of SEQ ID NO: 15. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 15, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 15. In certain aspects, the VH chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 14, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 14.

[0064] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VL chain sequence that includes one or more of the sequences of the CDRs of antibody B19C11 disclosed herein, i.e., the sequences of residues 24-38, 54-60, and 93-101 of SEQ ID NO: 17. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 17, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 17. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 16, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 16.

[0065] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 15, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 15, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 17, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 17.

[0066] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VH chain sequence that includes one or more of the sequences of the CDRs of antibody B33C12 disclosed herein, i.e., the sequences of residues 45-54, 69-87, and 116-127 of SEQ ID NO: 19. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 19, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 19. In certain aspects, the VH chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 18, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 18.

[0067] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VL chain sequence that includes one or more of the sequences of the CDRs of antibody B33C12 disclosed herein, i.e., the sequences of residues 44-58, 74-80, and 113-121 of SEQ ID NO: 21. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 21, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 21. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 20, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 20.

[0068] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 19, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 21, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 21.

[0069] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VH chain sequence that includes one or more of the sequences of the CDRs of antibody E12B11 disclosed herein, i.e., the sequences of residues 45-54, 69-85, and 116-131 of SEQ ID NO: 23. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 23, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 23. In certain aspects, the VH chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 22, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 22.

[0070] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VL chain sequence that includes one or more of the sequences of the CDRs of antibody E12B11 disclosed herein, i.e., the sequences of residues 24-34, 50-56, and 89-97 of SEQ ID NO: 25. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 25, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 25. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 24, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 24.

[0071] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:23, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:23, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:25, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:25.

[0072] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VH chain sequence that includes one or more of the sequences of the CDRs of antibody F8B30 disclosed herein, i.e., the sequences of residues 45-54, 69-85, and 116-125 of SEQ ID NO: 27. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 27, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 27. In certain aspects, the VH chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 26, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 26.

[0073] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VL chain sequence that includes one or more of the sequences of the CDRs of antibody F8B30 disclosed herein, i.e., the sequences of residues 24-34, 50-56, and 89-97 of SEQ ID NO: 29. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 29, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 29. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 28, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 28.

[0074] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:27, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:27, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:29, or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:29.

[0075] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VH chain sequence that includes one or more of the sequences of the CDRs of antibody G11B22 disclosed herein, i.e., the sequences of residues 45-54, 69-85, and 116-131 of SEQ ID NO: 31. In certain of these aspects, the VH chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 31, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 31. In certain aspects, the VH chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 30, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 30.

[0076] In certain aspects of the methods provided herein, the agent that reduces KIR2DL5 activity and / or expression is a KIR2DL5 antibody, immunogenic fragment thereof, or antibody fragment thereof, comprising a VL chain sequence that includes one or more of the sequences of the CDRs of antibody G11B22 disclosed herein, i.e., the sequences of residues 24-34, 50-56, and 89-97 of SEQ ID NO: 33. In certain of these aspects, the VL chain comprises, consists of, or consists essentially of an amino acid sequence set forth in SEQ ID NO: 33, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 33. In certain aspects, the VL chain is encoded by a nucleic acid sequence set forth in SEQ ID NO: 32, or a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence set forth in SEQ ID NO: 32.

[0077] In certain aspects of the methods provided herein, the agent that decreases the activity and / or expression of KIR2DL5 is a KIR2DL5 antibody, an immunogenic fragment thereof, or an antibody fragment thereof comprising a VH chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:31, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:31, and a VL chain comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO:33, or an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:33.

[0078] Based on the results disclosed herein showing that KIR2DL5 inhibits the function of human immune cells, in certain embodiments, the present specification provides a method for decreasing the function of human immune cells in a subject by increasing the expression and / or activity of KIR2DL5. Since hyperactivity of immune cells may be associated with autoimmune diseases, a method for treating autoimmune diseases in a subject by increasing the expression and / or activity of KIR2DL5 is further provided. Similarly, in transplantation situations where it is desired to suppress the immune system to prevent transplant rejection, decreasing the activity of immune cells may be useful. Thus, a method for decreasing transplant rejection by increasing the expression and / or activity of KIR2DL5 is also provided.

[0079] In certain embodiments of the methods described herein, KIR2DL5 activity and / or expression is increased in a subject by administering one or more agents that are KIR2DL5 agonists or PVR agonists. In certain embodiments, the agents increase the binding affinity of KIR2DL5 to PVR. In certain embodiments, the agents mimic KIR2DL5 by binding to and activating PVR.

[0080] In certain embodiments of the methods described herein, KIR2DL5 activity and / or expression is increased by administering one or more agents that increase activity of one or more pathways that upregulate KIR2DL5 expression. This increased activity can occur at any step in the pathway, for example, by activating a surface receptor, by increasing the interaction of two or more proteins within the cell, by activating the promoter region of KIR2DL5, etc.

[0081] Suitable agents for increasing the activity and / or expression of KIR2DL5 include, but are not limited to, peptides, polypeptides (eg, antibodies, fusion proteins) or small molecules.

[0082] In some embodiments, methods are provided for treating an autoimmune disorder in a subject in need thereof by increasing KIR2DL5 expression and / or activity as disclosed herein. In certain of these embodiments, the autoimmune disease or disorder is selected from the group consisting of acute disseminated encephalomyelitis (ADEM), alopecia areata, antiphospholipid syndrome, autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disorder, autoimmune lipoproliferative syndrome, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune thrombocytopenic purpura, autoimmune urticaria, autoimmune uveitis, Behcet's disease, celiac disease, Chagas disease, cold agglutinin disease, claudication, and rheumatoid arthritis. In one embodiment, the present invention relates to a method for treating or preventing the onset of atopic dermatitis, including the treatment of rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, rheumatoid arthritis, rheumatic fever, myasthenia gravis, psoriasis, psoriatic arthritis, relapsing polychondritis, rheumatoid arthritis, rheumatic fever, Sjogren's syndrome, temporal arteritis, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease, vasculitis, and Wegener's granulomatosis.

[0083] In some embodiments, methods are provided for decreasing transplant rejection in a subject in need thereof by increasing KIR2DL5 expression and / or activity. In certain of these embodiments, the transplant is selected from a stem cell transplant or a bone marrow transplant. In some embodiments, the transplant is selected from the group consisting of a kidney transplant, a lung transplant, a heart transplant, a pancreas transplant, a cornea transplant, or a liver transplant. In some embodiments, the activity and / or expression of KIR2DL5 is increased prior to transplant, i.e., at least one hour, at least one day, or at least one week prior to transplant; at the time of transplant; and / or after transplant.

[0084] This specification provides, in certain aspects, agents for use in the disclosed methods, i.e., agents that decrease or increase the activity and / or expression of KIR2DL5. These agents may be small molecules, peptides or polypeptides, including antibodies and fusion proteins, as disclosed herein. This specification also provides formulations (including pharmaceutical formulations) that contain such agents, and kits that contain the disclosed agents or formulations.

[0085] The above description and the following examples are only intended to illustrate various aspects of the present invention. The specific changes described above should not be interpreted as limiting the scope of the invention. It is clear to those skilled in the art that various equivalents, changes and modifications can be made without departing from the scope of the invention, and it is understood that such equivalent aspects are included in this specification. All references cited in the specification are incorporated by reference as if fully set forth in the specification. EXAMPLES

[0086] Example 1 Characterization of KIR2DL5 Binding In this example, it was confirmed that PVR-Ig protein binds to KIR2DL5 expressed in 3T3 cells in a dose-dependent manner, but not to KIR2DL4, a close homologue of KIR2DL5 (Figures 1 and 18A). PVR-Ig protein not only bound to wild-type KIR2DL5, but also to four KIR2DL5 D0 variants: T46S, R52H, G97S, and P112S (Figure 2). TIGIT, DNAM-1, and CD96 are known receptors for PVR and share a common binding site on PVR4. It was confirmed that KIR2DL5 and these three PVR receptors bind simultaneously to non-identical sites on PVR (Figure 3).

[0087] Specifically, cell-based binding assays were performed by incubating PVR-Ig fusion proteins with KIR2DL5- or KIR2DL4-expressing 3T3 cells. KIR2DL5 selectively bound to PVR but not to CD112 (also known as nectin-2), another ligand for the nectin / nectin-like family members TIGIT and DNAM-1 (Figure 10A). Furthermore, anti-KIR2DL5 mAb F8B30 blocked KIR2DL5-PVR interaction (EC 50 =0.095 μM) (Figure 10B). The binding specificity of KIR2DL5 to PVR was also demonstrated in a cell-cell interaction assay, where 3T3 cells expressing PVR interacted with 3T3 cells expressing KIR2DL5, but not with cells expressing KIR3DL3, a newly identified inhibitory receptor for HHLA2 (Figure 18B) (Zang, 2022; Wei 2021; Bhatt 2021). Figures 18B and 18C show that (i) KIR3DL3 / 3T3 cells interacted with HHLA2 / 3T3, but not with PVR / 3T3 cells; and (ii) the interaction between KIR2DL5 / 3T3 and PVR / 3T3 was blocked by the anti-KIR2DL5 mAb of the present technology.

[0088] In competition studies, DNAM-1, TIGIT and CD96 receptors did not block the interaction of PVR with KIR2DL5 (Fig. 10C), suggesting that KIR2DL5 bound to PVR through a non-identical site compared to the other PVR receptors.

[0089] Deletion of either D0 or D2 abolished binding to PVR (Fig. 10D), suggesting that both the D0 and D2 domains contribute to KIR2DL5-PVR interaction. * Compared to solid-state binding to 001, PVR binds cell surface-expressed 2DL5B * It was weakly bound to 00602, but 2DL5A * 005 or 2DL5B *003 did not bind (Figure S6E). As shown in Figure 2, substitution of glycine 97 in the D0 domain with serine (G97S) significantly enhanced PVR-Ig binding to KIR2DL5, whereas other D0 variants had only a minor effect on PVR-KIR2DL5 binding.

[0090] Example 2 Preparation of KIR2DL5 antibody Using previously reported methods, KIR2DL5 D0-Ig fusion protein was prepared by fusing the KIR2DL5 D0 coding region (H22-A128) to a human IgG1 Fc tag, and KIR2DL5 D0-D2-Ig fusion protein was prepared by fusing the KIR2DL5 D0D2 coding region (H22-H240) to a human IgG1 Fc tag (Zhao 2013). The fusion proteins were expressed in the S2 system and then purified. Mice were immunized with KIR2DL5 D0(H22-A128)-Ig fusion protein, and hybridomas were prepared from spleen cells fused to NSO myeloma cells by standard techniques.

[0091] The VH and VL sequences of the eight mAb clones are shown in Table 1 (CDRs are underlined and FRs are italicized). The binding affinities of these eight clones measured by Biolayer Interferometry are shown in Table 2.

[0092] [Table 1-1]

[0093] [Table 1-2]

[0094] [Table 1-3]

[0095] [Table 1-4]

[0096] [Table 2]

[0097] As shown in Figures 8A and 15B, eight anti-KIR2DL5 specific mAbs were prepared that did not cross-react with other KIRs. Clone F8B30 showed high affinity (K D = 0.72 nM) (Figures 15C and 15D). To determine the KIR2DL5 recognition pattern of the mAbs of the present technology, two truncated KIR2DL5 proteins were expressed by deleting the DO or D2 domains. As shown in Figures 8B and 15E, compared to UP-R1, which requires both the DO and D2 domains for KIR2DL5 recognition, several of the anti-KIR2DL5 mAbs disclosed herein, including F8B30, bound to KIR2DL5 at the DO domain.

[0098] In particular, FIG. 8C shows that F8B30, unlike UP-R1, inhibits cell surface-expressed 2DL5A * 8C and 16A, 2DL5B effectively recognized * 003 and 2DL5B * 00602 also bound to F8B30 and other clones.

[0099] Four D0 domain polymorphic variants, namely T46S, R52H, G97S and P112S, were identified in KIR2DL5A. * As shown in Figures 8D and 16B, all variants, including F8B30, were mutated to UP-R1 (EC 50 EC50% effective concentration (EC60) was significantly lower than the EC50% effective concentration (EC60; 391.1-875.9 nM). 50 8.6 to 43.6 nM) (Table 3). In summary, the results showed that the mAb of the technology of the present invention against the D0 domain of KIR2DL5 effectively recognized various KIR2DL5 alleles.

[0100] [Table 3]

[0101] Example 3 KIR2DL5 Expression Based on the performance of the mAbs of the present technology in recognizing KIR2DL5 over UP-R1 (see, e.g., Example 2), F8B30 was used to redefine the KIR2DL5 expression pattern in human immune cells. KIR2DL5 protein is expressed in innate (NK and γδ T cells) and adaptive (CD8 + In addition, KIR2DL5 was expressed on both immune cells (T cells) and inflammatory cells (Figs. 9A and 17A). + CD8 + T cells are primarily a terminally differentiated cell subset (T emra ), and to a lesser extent effector memory cell subsets, whereas KIR2DL5 expression was predominantly expressed in naive (T n ) and Central Memory (T cm )CD8 + It was very low or undetectable in T cells (FIG. 9B).

[0102] FACS analysis of PBMCs using the anti-KIR2DL5 mAb of Example 2 revealed that KIR2DL5 is widely expressed on the cell surface of innate immune cells (NK cells, γδ T cells) and adaptive immune cells (CD8 T cells, CD4 T cells) (Figure 4A). KIR2DL5 is expressed on the CD56 dim CD16+ NK cells (Figure 4B) and terminally differentiated effector memory CD8 T cells (T EMRA ) (Figure 4C).

[0103] According to the mRNA expression pattern (Fig. 17B), KIR2DL5 protein is mainly expressed on NK cells, especially on CD56 bright CD16 - CD56 is a more differentiated and cytolytic subset of dim CD16 +CD57 defines a highly mature, terminally differentiated and functionally distinct population of NK cells (Fig. 9C) (Moretta 2010). CD56 dim CD57 - A higher proportion of CD56 dim CD57 + PVR expressed KIR2DL5 (Figure 9D). Stimulatory cytokines such as IL-2, IL-12, IL-15, and IL-18 drive NK cell activation and maturation (Wu 2017). TIGIT, DNAM-1, and CD96 are well-documented receptors for PVR. TIGIT and CD96, but not KIR2DL5, were upregulated in response to exogenous stimulation with IL-2 and IL-15 (Figure 9E). In addition, KIR2DL5 was co-expressed with DNAM-1 and TIGIT, but its expression was mutually exclusive with CD96 expression in both resting and activated NK cells (Figure 9E). Finally, analysis of NK cell receptors by high-dimensional flow cytometry revealed that KIR2DL5 was upregulated by CD56 dim We found that it is clonally distributed within CD16 NK cells and is expressed coordinately with other NK cell receptors and KIRs (Figure 9F).

[0104] Example 4 Effect of KIR2DL5 on NK cell function Primary KIR2DL5+ NK cells were sorted and NK cell-based redirected cytotoxicity assays were performed as previously reported (Wei 2021). Binding of KIR2DL5 to CD16, but not to CD56, significantly inhibited P815 lysis (Figure 5A) and expression of CD107a, IFN-γ and TNF-α on NK cells (Figure 5B). Consistently, KIR2DL5 significantly reduced other cytokine and chemokine production by NK cells, including IL-13, IL-18, IL-25, IL-27, eotaxin, EGF, GM-CSF, M-CSF, RANTES, MIP-1α, MIP-1β, CXCL9, MCP-1 and MCP3 (Figure 5C).

[0105] To explore the effect of KIR2DL5-PVR engagement on NK-mediated tumor cell lysis, human tumor lines A427 (solid tumor) and Jurkat (hematological malignancy), which express endogenous PVR, were treated with CRISPR-Cas9 to knock out PVR (PVR ko A427, PVR ko Primary KIR2DL5+ NK cells were treated with either anti-KIR2DL5 blocking mAb F8B30 or control mIgG1 (Figure 5D). Anti-KIR2DL5 blocking mAb F8B30 significantly enhanced lysis of scrambled negative control A427 and Jurkat, but this effect was lost when PVR was knocked out in A427 and Jurkat. These results indicate that KIR2DL5 mediates tumor immune evasion by inhibiting NK cell function and by engaging PVR on tumor cells and KIR2DL5 on immune cells.

[0106] To examine whether KIR2DL5 directly inhibits primary NK cell function, we used human PBMC-derived KIR2DL5 + NK cells were sorted to confirm stable KIR2DL5 expression after activation and expansion (Figure 19A). High expression of other immunoinhibitory receptors, including KIR2DL1 / L2 / L3, TIGIT, CD96, and TIM3, as well as the immunostimulatory receptor NKG2D, was also observed in the expanded KIR2DL5 cells. + KIR2DL5 was detected on NK cells (Figure 19B). NK cell-based CD16-induced redirected cytotoxicity assay revealed that binding of KIR2DL5 to CD16, but not to CD56, significantly inhibited target cell P815 killing and NK cell degranulation (CD107a), as well as the production of IFN-γ and TNF-α (Figures 5A and 5B). By performing a 65-plex human cytokine / chemokine array experiment, it was observed that KIR2DL5 significantly reduced the production of a wide range of cytokines / chemokines, including IL-13, IL-18, IL-25, IL-27, eotaxin, EGF, GM-CSF, M-CSF, RANTES, MIP-1α, MIP-1β, CXCL-9, etc. (Figure 5C).

[0107] The effect of KIR2DL5-PVR engagement on NK-mediated tumor cell lysis was examined. Primary NK cells (Fig. 19C) were transduced with KIR2DL5 and co-cultured with human lung cancer A427 and leukemia Jurkat tumor cells, which express endogenous PVR. A427 and Jurkat cells displayed a characteristic expression profile of ligands for the NK cell receptor (Fig. 19D and 19E) and were susceptible to the killing action of NK cells. The presence of KIR2DL5 inhibited the expression of PVR. + It dramatically suppressed NK cell lytic activity against tumor cells (scrambled control), an effect that was abolished when PVR was deleted in tumor cells by CRISPR / Cas9 (PVR KO ) (Figures 5D, 19F and 19G). Similar observations were obtained with another leukemic K562 tumor cell line (Figures 19H and 19I).

[0108] To investigate whether KIR2DL5-PVR interaction mediates inhibitory synapse formation, we first cultured KIR2DL5 + NK cells were incubated with Raji cells expressing PVR-YFP (PVR / Raji) or control-YFP (controlRaji) fusion proteins (Figure 19J). In the absence of PVR on target cells, KIR2DL5 was evenly distributed on the NK cell surface, while F-actin was observed to accumulate at the interface, suggesting the formation of a lytic synapse (Figure 11A, top). In contrast, in the presence of PVR on target cells, clustering of KIR2DL5 with PVR was observed at the NK-Raji interface, but no polarization of F-actin was observed (Figure 11A, bottom), suggesting impaired actin reorganization and the formation of an inhibitory synapse.

[0109] Direct blockade of KIR2DL5, PVR + The effect of anti-KIR2DL5 mAb F8B30 disclosed herein, which effectively blocks the KIR2DL5-PVR interaction, on NK cell function against human tumors was examined. As shown in FIG. 11B (scrambled control), the anti-KIR2DL5 mAb F8B30 effectively blocks the KIR2DL5-PVR interaction. +F8B30 significantly enhanced tumor lysis by primary NK cells. The effect of F8B30 was also dependent on PVR, since in the absence of PVR, this mAb lost its enhancing effect on NK function (Figure 11B, PVR KO ).

[0110] Example 5. Effect of KIR2DL5 blockade The effect of KIR2DL5 blockade was evaluated in vivo using primary NK cells in three humanized mouse models. NSG mice were subcutaneously implanted with A427 and then treated intratumorally with expanded primary KIR2DL5+ NK cells as well as the anti-KIR2DL5 blocking mAb F8B30 or mIgG1. Compared to mIgG1, F8B30 significantly reduced tumor growth (Figure 6A) and increased mouse survival (Figure 6B).

[0111] Using a more physiologically relevant model of human lung cancer, mice were inoculated intravenously with A427 cells, then reconstituted with primary KIR2DL5+ NK cells and treated with F8B30 or mIgG1. Tumor growth in the lungs was significantly inhibited (Figure 6C) and survival was significantly extended (Figure 6D).

[0112] We next evaluated efficacy in a Jurkat xenograft tumor model of hematological malignancies. NSG mice were inoculated intravenously with Jurkat cells, then reconstituted with primary KIR2DL5+ NK cells and treated with F8B30 or mIgG1. In vivo tumor growth was significantly inhibited (Figure 6E) and survival was significantly prolonged (Figure 6F).

[0113] Specifically, when incubated with the anti-KIR2DL5 blocking mAb F8B30, KIR2DL5 + NK cells are PVR +After co-culture with A427 (Fig. 14A) or Jurkat tumor cells (Fig. 14B), they displayed stronger cytotoxicity, degranulation (CD107a), and functional cytokine (IFN-γ and TNF-α) production. TIGIT expression was low in resting NK cells, but increased upon activation with IL-2 and IL-15 (Fig. 9E). Blockade of TIGIT on activated NK cells promoted NK degranulation (Fig. 22A), confirming its inhibitory role in regulating NK cell function. KIR2DL5 + Despite the high expression of TIGIT on NK cells (Fig. 19B), blocking TIGIT alone did not alter NK cytotoxicity. Enhancement of tumor lysis and NK degranulation was observed only when KIR2DL5 was blocked alone or together with TIGIT blockade (Figs. 14C and 22B). + TIGIT + It is suggested that it has a more dominant role than TIGIT in inhibiting NK cytotoxicity.

[0114] We also investigated the enhancement of NK cell function by KIR2DL5 blockade in vivo. Humanized non-obese diabetic (NOD) mice were used because mice do not express the KIR2DL5 homologue. scid Il2rg tm1Wjl A subcutaneous tumor model was first used, in which NSG mice were implanted with A427 cells and then transfected with KIR2DL5 + Intratumoral reconstitution with primary NK cells was followed by treatment with F8B30 or isotype control (Figure 14D). Compared to mIgG1 treatment, blocking KIR2DL5 significantly inhibited tumor growth as evidenced by a significant reduction in tumor volume (Figure 6A) and improved overall mouse survival (Figure 6B). Similar results were obtained in NSG-hIL-15 mice expressing human IL-15, providing better support for human NK cell survival after cell transfer (Figures 22C-22E).

[0115] We next tested the antitumor effects of F8B30 in a physiologically more relevant lung tumor model. + A427 tumor cells (A427-luc2) were inoculated i.v. and KIR2DL5 + Primary NK cells and F8B30 or mIgG1 were treated (Figure 14E). Tumor growth in the lungs was monitored by bioluminescence. F8B30-treated mice showed significantly lower tumor growth than mIgG1-treated mice (Figures 14F and 6C). All mIgG1-treated mice reached the endpoint within 40 days, whereas two of five F8B30-treated mice were tumor-free more than 70 days after tumor inoculation (Figure 6D). In the Jurkat-luc2 tumor model, F8B30 inhibited tumor inoculation and adoptive transfer of KIR2DL5 + Tumor dissemination following NK cell transfer was significantly reduced and overall mouse survival was extended (Figures 14G-14H and 6E-6F).

[0116] Collectively, these results indicate that blocking KIR2DL5-PVR restores immune cell effector functions and promotes antitumor immunity in vitro and in vivo.

[0117] Example 6 KIR2DL5-induced inhibitory signaling in NK cells The downstream signaling pathways induced by KIR2DL5 were investigated in human NK cells. Upon initiation of KIR2DL5 signaling, we observed a substantial reduction in Vav1, ERK1 / 2, RSK, and NF-kB activation in CD16-stimulated KIR2DL5+ primary NK cells (Figures 7A and 7B), suggesting that KIR2DL5 induces an inhibitory signal in human NK cells.

[0118] As shown in Figure 15, the cytoplasmic tail of KIR2DL5 has a classical ITIM and ITSM. Tyrosine residues were mutated to phenylalanine in the ITIM (Y298F) or ITSM (Y328F), or both (Y298F / Y328F) (Figure 12A). WT KIR2DL5 and mutated KIR2DL5 were compared. -We transduced KIR2DL5 into primary NK cells, and its expression level after cell sorting was similar (Fig. 12A). Upon treatment with pervanadate, a tyrosine phosphatase inhibitor (Huyer 1997), WT KIR2DL5 showed tyrosine phosphorylation, whereas the mutants showed reduced or absent tyrosine phosphorylation (Fig. 12B and 12C). We verified that both SHP-1 and SHP-2 were recruited by WT KIR2DL5 in primary NK cells (Fig. 12B) (Estefania 2007; Yusa 2004). Notably, we found that the association of KIR2DL5 with SHP-1 was impaired by tyrosine mutations in the ITIM or ITSM (Fig. 12B and 12C). KIR2DL5-mediated recruitment of SHP-2 was completely abolished by tyrosine mutations in the ITIM but not in the ITSM (Fig. S12B and S12C). As shown in Fig. S12D, such mutations did not affect the clustering of KIR2DL5 with PVR at the interface of the immune synapse. However, the inhibition of NK cytotoxicity mediated by the PVR-KIR2DL5 interaction was impaired when either or both of the ITIM or ITSM were mutated (Fig. S12E).

[0119] We performed receptor cross-linking assays to initiate KIR2DL5 signaling in CD16-stimulated primary NK cells, which were then subjected to human phospho-kinase array analysis. Compared to CD16 alone, binding of KIR2DL5 to CD16 reduced the phosphorylation levels of multiple kinases, including ERK1 / 2 and p90RSK (Figures 20A and 20B). Furthermore, immunoblot analysis revealed reduced activation of Vav1, ERK1 / 2, p90RSK, and the downstream transcription factor NF-κB upon initiation of KIR2DL5 signaling (Figures 7A and 7B).

[0120] Example 7 Various PVRs in humans + KIR2DL5 infiltrating cancer + immune cells To further understand the KIR2DL5 / PVR pathway in the human tumor microenvironment, we analyzed datasets from the Gene Expression Omnibus and BloodSpot databases. KIR2DL5A mRNA was found to be upregulated in several human solid tumors and hematopoietic malignancies compared to corresponding normal tissues (Figures 21A and 21B), whereas other receptors TIGIT, CD96, and DNAM-1 were found to be higher, lower, or no difference in these tumors compared to corresponding normal tissues (Figure 21A).

[0121] To further explore the KIR2DL5 / PVR pathway in various human cancers, we first attempted immunohistochemistry (IHC) staining for KIR2DL5, but none of the antibodies worked. We used RNAScope™ in situ hybridization to examine KIR2DL5 mRNA expression on human tumor tissue microarrays (TMAs) using a KIR2DL5-specific probe (Niu, 2022). The probe set for KIR2DL5A was KIR2DL5A. + NK cells were specifically stained, whereas KIR2DL5 - PBMCs did not stain (Figure 21C). + CD45 + Tumor-infiltrating immune cells were found in a wide range of human cancers (Figure 13 and Table 4). The expression of PVR protein in such tumors was examined. IHC staining revealed that PVR protein was widely expressed in such cancers (Figure 13 and Table 4). These results indicate that the immunosuppressive KIR2DL5 / PVR pathway exists in the TME of various human cancers of the bladder, kidney, breast, lung, liver, cerebral, prostate, colon, esophagus, pancreas, uterus, and stomach, and may be exploited by tumors as an immune evasion mechanism.

[0122] [Table 4]

[0123] mouse BALB / c mice were purchased from Charles River Laboratory. SCID Il2rg tm1Wjl NSG / SzJ (NSG) and NSG-IL-15 mice were purchased from The Jackson Laboratory. Mice were used at 6-8 weeks of age. All mice were bred and maintained in a pathogen-free facility with a 12-h light / dark light cycle at the Albert Einstein College of Medicine (Bronx, New York, USA).

[0124] cell lineage Human cell lines used herein include Phoenix-ampho, a retroviral producer line (ATCC, CRL-3213); HEK293T, a lentiviral producer line (obtained from Dr. Wenjun Guo, Department of Cells Biology, Albert Einstein College of Medicine); K562, human chronic myeloid leukemia (ATCC, CCL-243); Jurkat, human T-lymphoblastic leukemia cell line (ATCC, TIB-152); Raji, human B-cell lymphoma (ATCC, CCL-86) and A427, human lung adenocarcinoma (obtained from Dr. Haiying Cheng, Department of Cells Biology, Albert Einstein College of Medicine). These cell lines were cultured in either EMEM, DMEM or RPMI1640 (Gibco) medium supplemented with 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin. The mouse cell lines used herein were the mouse fibroblast line NIH 3T3 (ATCC, CRL-1658), the mouse mast cell line P815 (ATCC, TIB-64) and the mouse myeloma cell line NSO (obtained from Dr. Matthew D. Scharff, Department of Cells Biology, Albert Einstein College of Medicine). Cells were cultured in DMEM supplemented with 10% FBS, 100 U / mL penicillin and 100 μg / mL streptomycin. All cell lines were cultured at 37° C. in a humidified atmosphere containing 5% CO2.

[0125] Human phosphokinase array The phosphorylation profile of downstream kinases in the PVR / KIR2DL5 pathway was determined by using a human phospho-kinase array (R&D Systems). + Primary NK cells (5 x 10 6) were preincubated with 10 μg / mL of isotype control mIgG1 or anti-KIR2DL5 mAb (clone F8B10) in the presence of anti-CD16 (5 μg / mL) on ice for 30 min. After washing with medium, primary NK cells were crosslinked with 25 μg / mL of goat anti-mouse IgG (minimal X-reactivity) (BioLegend) for 2 min at 37° C. in a water bath. The reaction was stopped by quickly transferring the cells to ice and then lysed in cell lysis buffer, and the relative levels of protein phosphorylation were subsequently analyzed according to the manufacturer's instructions.

[0126] Preparation and purification of human fusion proteins KIR2DL5-Ig was prepared in an inducible secretory serum-free Drosophila expression system as previously described (Wei 2021; Zhao 2013). Briefly, the coding region of the extracellular domain without the signal peptide of KIR2DL5 was fused to a human IgG1 Fc tag in a pMT / BiP vector. The construct was co-transfected with a blasticidin resistance plasmid into Drosophila Schneider 2 (S2) cells by calcium phosphate transfection kit (Invitrogen). Stably transfected S2 cells were selected and grown in Schneider's Drosophila medium (Gibco) supplemented with 10% FBS, 100 U / mL penicillin, 100 μg / mL streptomycin, and 25 μg / mL blasticidin (Gold Biotechnology). S2 cells were induced to secrete the fusion protein in Express Five serum-free medium (Life technologies) in the presence of 0.75 mM CuSO4. Proteins were purified using a Protein G resin (GenScript) column.

[0127] Preparation of stable cell lines Molecules expressed in NIH 3T3 and Raji cells were introduced by retroviral transduction. Retroviruses were prepared using jetPRIME reagent (Polyplus Transfection) in Phoenix-ampho cells transfected with pCMV-VSV-G and MSCV-YFP containing the gene of interest.

[0128] Molecules expressed in A427, Jurkat and K562 were introduced by lentiviral transduction. Lentivirus was prepared in HEK293T cells transfected with pCMVR8.74, pCMV-VSV-G and lentiviral backbone vectors containing the gene of interest using jetPRIME reagent (Polyplus transfection). Virus-containing supernatants were harvested 48-72 hours after transfection and filtered through a 0.45 μm filter. Cells were spin-infected for 120 min at 2000 g and 37°C in the presence of 5 μg / mL polybrene (Merck Millipore) and 1-2 mL of viral supernatant. Transduced cells were sorted using a BD FACSAria Fusion Cell Sorter (BD Biosciences).

[0129] Fusion protein cell binding assay PVR-Ig, CD112-Ig or hIgG (R&D Systems) were incubated with the corresponding 3T3 cells for 45 min on ice, followed by incubation with APC or PE-conjugated anti-human IgG Fc antibody (1:100; clone HP6017, BioLegend) for 30 min on ice. Cells were then acquired on an LSR II flow cytometer (BD Biosciences). For anti-KIR2DL5 mAb blocking assays, KIR2DL5 / 3T3 cells were pre-incubated with serial concentrations of anti-KIR2DL5 mAb F8B30 or mIgG1 for 30 min on ice. After washing, cells were incubated with 20 μg / mL PVR-Ig or hIgG for 45 min on ice, followed by incubation with APC anti-human IgG Fc antibody for 30 min on ice. For PVR receptor competitive binding assays, PVR-YFP / 3T3 cells were preincubated with recombinant human DNAM-1-His (R&D Systems), TIGIT-His (R&D Systems) or CD96-His (Thermo Fisher Scientific) tagged proteins at the indicated concentrations for 40 min at room temperature (RT). KIR2DL5-Ig (20 μg / mL) protein was then incubated with PVR-YFP / 3T3 cells for 45 min on ice, followed by PE anti-human IgG Fc (1:200; BioLegend) for 30 min on ice. In the reverse orientation, PVR-Ig protein (20 μg / mL) was preincubated with His-tagged proteins at the indicated concentrations, then stained with KIR2DL5 / 3T3 cells for 45 min on ice, followed by PE anti-human IgG Fc for 30 min on ice. Cells were then acquired on an LSR II (BD Biosciences).

[0130] Cell-cell conjugation assay To distinguish each other, PVR / 3T3 and HHLA2 / 3T3 cells were pre-labeled with eFluor450 (eBioscience), and KIR2DL5 / 3T3 and KIR3DL3 / 3T3 were pre-labeled with PKH26 (Sigma-Aldrich). PVR / 3T3 or HHLA2 / 3T3 cells (2 × 105 ) with KIR2DL5 / 3T3 or KIR3DL3 / 3T3 (2 × 10 5 ) for 45 min at 37°C. For mAb blocking assays, PVR / 3T3 cells were incubated with KIR2DL5 / 3T3 or KIR3DL3 / 3T3 cells in the presence of anti-KIR2DL5 mAb or mIgG1 (10 μg / mL). After washing, cells were harvested on an LSR II (BD Biosciences) to analyze cell-cell conjugation.

[0131] Preparation of mAb against KIR2DL5 Mouse anti-KIR2DL5 mAb was prepared by hybridoma technology as previously described (Wei 2021; Zhao 2013). Briefly, spleen cells from KIR2DL5-Ig immunized BALB / c mice were fused with NSO myeloma cells. Eight clones that specifically recognized KIR2DL5 were selected by high-throughput flow cytometry. Hybridoma cells were cultured in CELLine350 Bioreactor flasks (DWK Life Sciences). Antibodies were purified from hybridoma supernatants by protein G resin (GenScript) columns. Purity and integrity of the antibodies were determined by SDS-PAGE and FACS. For the following analyses, clone F8B30 was conjugated with PE by SiteClick R-PE Antibody Labeling kit (Invitrogen).

[0132] Biolayer Interferometry The affinity of anti-KIR2DL5 mAb was analyzed by biolayer interferometry using the Octet RED96 system (ForteBio, Pall LLC). Briefly, anti-human Fc capture biosensors (ForteBio, Pall LLC) were preloaded with KIR2DL5-Ig and then immersed in solutions containing 2-fold serially diluted (200–1.5 μg / mL) mAb. Data were analyzed using Forte Pall (Port Washington, New York, USA) software 9.0. Global data fitting to a 1:1 binding model was performed using the K on (binding rate constant), K off (dissociation rate constant) and K D (equilibrium dissociation constant).

[0133] Immunophenotyping by flow cytometry Monoclonal antibody against KIR3DL3 (clone 26E10) was purified in-house (Wei 2021). The following fluorophore-conjugated antibodies were used (all antibodies were obtained from BioLegend unless otherwise noted) (see Table 5): CD3 (clone UCHT1, BD Biosciences), CD4 (clone RPA-T4), CD8 (clone RPA-T8, BD Biosciences), CD16 (clone 3G8, BD Biosciences), and CD16 (clone 1G8, BD Biosciences). Biosciences), CD19 (clone SJ25C1), CD56 (clone 5.1H11), anti-human CD57 (clone QA17A04), TCRγδ (clone B1), CCR7 (clone G043H7), CD45RA (clone HI100), CD155 (clone SKII.4), DNAM-1 (clone 11A8), TIGIT (clone A15153G), CD96 (clone NK92.39), CD107a (clone H4A3), IFN-γ (clone B27) , TNF-α (clone MAb11), CD57 (clone HNK-1), KLRG1 (clone SA231A2), KIR3DL2 (clone 539304, R&D), KIR2DL1 / S1 / S3 / S5 (clone HP-MA4), KIR2DL2 / 3 (clone DX27), KIR2DL4 (clone mAb33), KIR2DL5 (clone UP-R1), NKG2D (clone 1D11), NKG2C (clone 134591, R&D), NKG2A (clone 131411, BD Biosciences), 2B4 (clone C1.7), NKp46 (clone 9E2), NKp44 (clone p44-8, BD Biosciences), NKp30 (clone p30-15, BD Biosciences).

[0134] Human PBMCs were stained with Zombie Violet Fixable Viability kit (BioLegend) and then incubated with FcR blocking reagent (Miltenyi Biotec). For surface marker staining, cells were incubated with specific antibodies for 30–45 min at 4°C. For CD107a and intracellular cytokine staining, cells were incubated with anti-CD107a for 5 h in the presence of 5 μg / mL brefeldin A and 2.5 μg / mL monensin (BioLegend). Cells were then fixed and permeabilized using Fixation / Permeabilization Solution kit (BD Biosciences) according to the kit manufacturer's instructions, followed by staining with intracellular antibodies for 30–45 min at 4°C. All samples were acquired on an LSR II (BD Biosciences) or Aurora (Cytek) and analyzed using FlowJo software (BD Biosciences). The DownSample and t-SNE plugins in FlowJo and the ggplot2 package in R were used to generate t-SNE plots.

[0135] Isolation and culture of human NK cells Human PBMCs were isolated from buffy coats of healthy donors purchased from the New York Blood Center using Ficoll-Hypaque (GE Healthcare) density gradient separation. +Primary NK cells were sorted by FACS and then expanded using autologous PBMCs as feeder cells (irradiated at 30 Gy, feeder cells:NK cells = 20:1) by culturing in OpTimizer (Invitrogen) supplemented with 5% human AB serum (Sigma-Aldrich), 1% L-glutamine, 100 U / mL penicillin, 100 μg / mL streptomycin, anti-CD3 OKT3 (10 ng / mL; BioLegend), recombinant human IL-2 (40 ng / mL; BioLegend) and IL-15 (10 ng / mL; BioLegend). After 5 or 6 days, NK cells were further expanded in the same medium without anti-CD3 and feeder cells.

[0136] Primary NK cell transduction KIR2DL5 wild type and KIR2DL5 - The ITIM / ITSM variants expressed on the surface of primary NK cells were introduced by lentiviral transduction. psPAX, pMD2.G, and KIR2DL5A were transfected using jetPRIME reagent (Polyplus transfection). * Lentivirus was prepared in HEK293T cells co-transfected with lentiviral backbone pSin vector (obtained from Dr. Alec Zhang's laboratory (Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA)) containing the full-length gene sequence of .001. Virus-containing supernatants were harvested 48–72 h after transfection and filtered through a 0.45 μm filter. Non-tissue culture-treated plates were coated with retronectin, and then the viral supernatant was incubated on the plate surface at 2,000 g and 37°C for 120 min. NK cells were then spun down at 1000 g and 37°C for 10 min. Transduced NK cells were sorted using a BD FACSAria Fusion cell sorter (BD Biosciences).

[0137] Cytotoxicity assay Cytotoxicity assays were performed by flow-based assay. Briefly, target cells were labeled with PKH26 (Sigma-Aldrich) for 2 min at 37° C. For mAb blocking assays, primary NK cells were preincubated with 20 μg / mL mIgG1, anti-KIR2DL5 mAb (clone F8B30), anti-TIGIT mAb (clone MBSA43, eBioscience), or the indicated combinations for 30 min and then co-cultured with target cells.

[0138] In the CD16-induced redirected cytotoxicity assay, anti-human CD16 mAb (clone 3G8) was used to activate NK cells by cross-linking of CD16. Briefly, P815 cells were preincubated for 15 min at RT with 0.5 μg / mL anti-human CD16 and 2 μg / mL mIgG1, anti-KIR2DL5 mAb (clone F8B30) or anti-CD56 (clone 5.1H11). Target cells were incubated with effector NK cells at the indicated E / T ratios in 96-well round-bottom plates for 4–6 h at 37°C. Supernatants from the redirected cytotoxicity assay were collected 24 h after co-culture for the Human Cytokine 65-Plex assay (Eve Technologies). 7-AAD was used to distinguish dead from viable cells. Standard formula (100×PKH26 + 7-AAD + Cell / PKH26 + The % cells was used to calculate the % lysis.

[0139] NK-Raji conjugation assay KIR2DL5 + Primary NK or NK cells transduced with KIR2DL5 WT, Y298F, Y328F or Y298 / 328F mutants (5 × 10 5 ) to 5 x 10 5The cells were incubated with 1000 PVR-YFP / Raji or YFP / Raji cells in a 50 mL tube at 37°C for 40 min. The cell mixture was then loaded onto poly-L-lysine pre-coated slides and fixed with 4% formaldehyde for 15 min at RT. After blocking with 5% goat normal serum for 1 h at RT, the cells were stained with 20 μg / mL anti-KIR2DL5 antibody (8 homemade clone mixture) at 4°C overnight and then with goat anti-mIgG(H+L)Alexa Flour647 (Invitrogen) for 2 h at RT. The cells were permeabilized with 0.1% Triton®X-100 for 15 min at RT and stained with Alexa Flour Plus 405 Phalloidin (Life technologies) for 1 h at RT. The slides were then mounted in Gold Antifade Mountant without DAPI (Life technologies). The average pixel intensity of synapses and non-synapses was measured and statistically analyzed. Images were acquired with a Leica SP8 confocal microscope and processed with ImageJ (NIH).

[0140] Plasmid construction and site-directed mutagenesis A plasmid encoding KIR2DL5 was purchased from the Molecular Cytogenetics Core at the Albert Einstein College of Medicine, and a fragment of KIR2DL5 was inserted into the MSCV-YFP vector. Mutagenesis was performed using the New England Biolabs Q5 Site Directed Mutagenesis kit.

[0141] The mutant KIR2DL5 was amplified using the following primers: truncated D0 forward, GGTCTATTTGGGAAACCTTCACTCTCAG (SEQ ID NO: 34); Deletion type D0 reverse, TGTCCAGGCCCCCTGCAG (SEQ ID NO: 35); truncated D2 forward, GGAAACTCTTCAAGTAGTTCATC (SEQ ID NO: 36); Truncated D2 reverse, TGTGACCACGATCACCAG (SEQ ID NO: 37); N173D forward, GCCCAGCGTCGATGGAAACATTCC (SEQ ID NO: 38); N173D reverse, ACTGCAGGGAGCCTAGGTT (SEQ ID NO: 39); 2DL5A * N173D / G195S for 005 forward, CACATGCTTCAGCTCTCTCCATGAC (SEQ ID NO: 40); 2DL5A * N173D / G195S for 005 reverse, TAGGTCCCTCCGTGGGTG (SEQ ID NO: 41); I6V forward, GCTCATGGTCGTCAGCATGGCGT (SEQ ID NO: 42); I6V reverse, GACATAGATCTAATCCGGCGC (SEQ ID NO: 43); 2DL5B * I6V / T21P for 00602 forward, GGGGCCTGGCCACATGAGGGTG (SEQ ID NO: 44); 2DL5B * I6V / T21P for 00602 reverse, TGCAGCAAGAAGAACCCAACACAC (SEQ ID NO: 45); 2DL5B * I6V / T21P / V116M for 003 forward, CCTGGTGATCATGGTCACAGGTC (SEQ ID NO: 46); 2DL5B * I6V / T21P / V116M for 003 reverse, GGGTTGCTGGGTGCTGAC (SEQ ID NO: 47); T46S forward, GGACATGTGAGTCTTCTGTGTCGC (SEQ ID NO: 48); T46S reverse, TCCTCGAGGCACCACAGC (SEQ ID NO: 49); R52H forward, TGTCGCTCTCATCTTGGGTTTAC (SEQ ID NO:50); R52H reverse, CAGAAGAGTCACATGTCC (SEQ ID NO:51); G97S forward, CAGATGTCGGAGTTCACACCCAC (SEQ ID NO:52); G97S reverse, TAGGTCCCTGCGTGTGCA (SEQ ID NO:53); P112S forward, ACCCAGCAACTCCCTGGTGAT (SEQ ID NO:54); P112S reverse, GCTGACCACTCAATGGGG (SEQ ID NO:55); Y298F forward primer, GGAGGTGACATTTGCACAGTTGG (SEQ ID NO:56); Y298F reverse primer, TGAGGGTCTTGATCATCAG (SEQ ID NO:57); Y328F forward primer, TACCACCATGTTCATGGAACTTC (SEQ ID NO:58); Y328F reverse primer, TCTGTTGGAGGTGTCTTG (SEQ ID NO:59) Constructed using.

[0142] To construct the pSin-KIR2DL5 WT vector and mutants, the following primers were used: pSin forward, TGTCGTGAGGAATTGATCCTTCGAACTAGTATGTCGCTCATGGTCATCAG (SEQ ID NO: 60); pSin reverse primer, TGTAAGTCATTGGTCTTAAAGGTACCTGAGGTCAGATTCCAGCTGCTGGT (SEQ ID NO: 61) was used.

[0143] The restriction enzyme sites were Bsu36I and SpeI.

[0144] Lentiviral CRISPR / Cas9-induced deletion of PVR. Scrambled control sgRNA and sgRNA targeting PVR were designed using GPP sgRNA Designer (Doench 2016) (https: / / portals.broadinstitute.org / gpp / public / analysis-tools / sgrna-design). Oligonucleotides were annealed in T4 DNA-ligase buffer (New England Biolabs) and cloned into lentiCRISPR version 2 (Addgene, 52961).

[0145] The sgRNA sequences were as follows: Scrambled control sgRNA: 5'-GCACTACCAGAGCTAACTCA-3' (SEQ ID NO:62); sgRNA no.1 targeting PVR: 5'-GATGTTCGGGTTGCGCGTAG-3' (SEQ ID NO: 63); sgRNA no. 2 targeting PVR: 5'-TTGAGGGCACCAATATCCAG-3' (SEQ ID NO: 64).

[0146] None of these constructs are predicted to target known sequences in the human genome. Lentiviruses were prepared as previously described. A427 and K562 were transduced with viral supernatants and then selected with puromycin (2 μg / mL) for 3 days. Stable knockout of PVR (PVR KO) was confirmed by flow cytometry analysis.

[0147] Co-immunoprecipitation and immunoblotting NK92 cells or primary NK cells pretreated with or without 1 mM pervanadate (New England BioLabs) were lysed in Pierce immunoprecipitation lysis buffer supplemented with protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Proteins from whole cell lysis were further incubated with anti-KIR2DL5 antibody and Dynabeads Protein G (Thermo Fisher Scientific) for further immunoprecipitation. To analyze phosphorylation status, cells were lysed after receptor crosslinking in radioimmunoprecipitation lysis buffer (50 mM Tris-HCl [pH 7.5], 0.15 M NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease and phosphatase inhibitor cocktail. Samples were resolved on SDS-PAGE gels (GenScript) and transferred to nitrocellulose membranes (Bio-Rad) for protein detection.

[0148] The following antibodies: anti-phospho-tyrosine 4G10 (1:1,000; Sigma-Aldrich), anti-SHP-1 (1:500; Cell Signaling Technology [CST]), anti-SHP-2 (1:500; anti-Vav1 (1:2,000; CST), anti-phospho-Vav1). Tyr160 (1:2,000; Invitrogen), anti-ERK1 / 2 (1:2,000; CST), anti-phospho-ERK1 / 2 Thr202 / Tyr204 (1:1000; BioLegend), anti-p90RSK (1:1,000; CST), anti-phospho-p90RSK Thr359 / Ser363(1:1000;CST), anti-phospho-NF-κB p65 Ser536 (1:1,000; CST), anti-β-actin (1:2,000; Santa Cruz Biotechnology), HRP-conjugated goat anti-mouse (1:1,0000; Jackson ImmunoResearch), rabbit anti-goat (1:1,0000; Jackson ImmunoResearch), and goat anti-rabbit (1:2,000; CST) secondary antibodies, as well as enhanced chemiluminescence substrate (ECL; Bio-Rad), were used.

[0149] RNAScope™ in ISH and Imaging RNAScope™ ISH for KIR2DL5 and CD45 mRNA expression in FFPE human tumor tissue microarrays (TMAs; US Biomax) was performed using the RNAScope™ 2.5HD Reagent Kit (Advanced Cell Diagnostics) according to the manufacturer's instructions (Wang 2012). Briefly, TMA slides were deparaffinized and antigen-retrieved using citrate buffer at boiling temperature for 15 min, then treated with 10 μg / mL protease at 40°C for 30 min. Probes were hybridized at 42°C for 2 h, followed by signal amplification. For fluorescent detection, label probe sets for KIR2DL5 and CD45 were conjugated to Opal570 and 690 nm (Akoyo Biosciences), respectively. To assess both tissue RNA integrity and background signal, assays were routinely performed in parallel with positive (UBC) and negative (bacterial gene dapB) controls. Slides were scanned using a 3DHistech P250 high-performance slide scanner with 3 channels using filter settings for DAPI, FITC, and Cy7. Staining was analyzed by trained researchers using Volocity software.

[0150] IHC staining and imaging The same cohort of TMAs used in RNAScope™ ISH were deparaffinized followed by antigen retrieval in a steamer at sub-boiling temperatures (95°C-98°C) for 20 min with citrate unmasking buffer (CST). Slides were then blocked with 3% hydrogen peroxidase solution for 10 min at RT followed by 10% normal goat serum for 1 h at RT. Rabbit anti-PVR (clone D8A5G, CST) mAb was used at a dilution of 1:200 for overnight incubation at 4°C. Slides were then incubated with boost detection reagent (HRP, CST) for 30 min at RT followed by SignalStain DAB (CST) and hematoxylin nuclear counterstaining. Positive and negative controls (FFPE cell clumps) were included for each staining.

[0151] Human cancer xenograft models For the subcutaneous A427 tumor model, 3 × 10 6 Three or five days later, mice were randomized into two groups (n=6 or 8) and treated with KIR2DL5 + Primary NK cells (1×10 7 ), and 200 μg of anti-KIR2DL5 mAb (clone F8B30) or isotype control (mIgG1) were intratumorally treated (once every 3 days). Tumors were measured by caliper and tumor volumes were calculated (width x width x height). 2 × length) / 2.

[0152] For the intravenous A427 tumor model, NSG mice were inoculated with 1 × 10 6 Mice were intravenously (iv) injected with 100 luciferase-expressing A427 cells (A427-luc2). One day later, mice were subjected to bioluminescence imaging (BLI) and assigned to two groups (n=5) based on similar mean photon flux (photons / second). Mice were then transfected with KIR2DL5 + Primary NK cells (1×10 7) and treated twice iv (once every 3 days) with 200 μg of F8B30 or mIgG1. Lung tumor growth was monitored weekly by BLI, with a total photon flux of 1×10 8 Mice were euthanized when photons / sec was reached.

[0153] For the intravenous Jurkat tumor model, NSG mice were injected with 5 × 10 5 After 4 days, mice were assigned to two groups (n=4 or 6) based on similar mean photon flux (photons / sec) and KIR2DL5 + Primary NK cells (1×10 7 ) and 200 μg of F8B30 or mIgG1 were treated iv twice (once every 3 days). Tumor growth was monitored by BLI with a total photon flux of 1×10 8 Mice were euthanized when photons / sec was reached. For all BLI, mice were administered D-luciferin (150 mg / kg; Gold Biotechnology) by intraperitoneal injection for 10 min prior to imaging. Data were analyzed using Living Image 3.0 software.

[0154] Data Availability and Statistical Analysis Previously published Gene Expression Omnibus (GEO) data reanalyzed here are available under accession codes GSE7904, GSE19069 and GSE39612.

[0155] Statistical analyses were performed in GraphPad Prism, version 9.0 (GraphPad Software) using the appropriate tests as indicated in the figure legends (unpaired two-tailed t-test, paired two-tailed t-test, one-way analysis of variance followed by Tukey or Dunnett's multiple comparison test, two-way analysis of variance followed by Sidak's multiple comparison test, multiple t-test, and Kaplan-Meier log-rank test for survival curves). Data are expressed as mean ± SEM for n = 3 or more determinations. P values ​​< 0.05 were considered statistically significant.

[0156] [Table 5-1]

[0157] [Table 5-2]

[0158] [Table 5-3]

[0159] Consideration Human KIRs are crucial regulators of NK cell function and are also important for immune tolerance and tumor surveillance (Pende 2019). KIR2DL5 is a very recently identified KIR molecule (Estefania 2007). PVR, a nectin / nectin-like family protein, was recently identified as a binding partner for KIR2DL5 (Verschueren 2020; Husain 2019).

[0160] This example shows that KIR2DL5 suppresses primary NK cytotoxicity against multiple solid and hematopoietic tumor cells in a PVR-dependent manner. KIR2DL5-induced inhibitory signaling in primary NK cells. Blockade of KIR2DL5 using blocking mAbs of the present technology significantly enhanced NK-mediated anti-tumor immunity both in vitro and in vivo, demonstrating blockade of the KIR2DL5 / PVR pathway as an immunotherapy for treating human cancers.

[0161] The identification of KIR2DL5 as an inhibitory receptor for PVR adds it to a complex regulatory network consisting of two other inhibitory receptors for PVR, TIGIT and CD96, and one activating receptor, DNAM-1. Unlike TIGIT and CD96, which share a common binding site on PVR with DNAM-1 (Yu 2009), KIR2DL5 bound to a non-identical site on PVR and did not compete with these three receptors for PVR binding, suggesting a different mechanism by which KIR2DL5 exerts its inhibitory effect upon engagement with PVR. KIR2DL5 mediates the inhibition of PVR on NK cell killing. + Furthermore, KIR2DL5-mediated inhibition of NK cytotoxicity was abolished when PVR was depleted on tumor cells. These findings support PVR as a primary ligand for KIR2DL that induces NK cell suppression and tumor immune evasion.

[0162] Allelic polymorphisms have a significant effect on KIR cell surface expression, antibody recognition, and ligand avidity (Carr 2005; Campbell 2011). Unlike UP-R1, which requires both the D0 and D2 domains for KIR2DL5 recognition, the anti-KIR2DL5 mAb F8B30 of the present technology binds to KIR2DL5 at the D0 domain, suggesting that it recognizes a distinct epitope on KIR2DL5. * In addition to the 001 and D0 variants, F8B30 also harbors the surface-expressed 2DL5A , the second most common 2DL5A allele in humans. * 005, but not UP-R1. Furthermore, PVR showed different binding abilities to different KIR2DL5 alleles. * Compared to 001, 2DL5B * 00602 binds moderately to PVR and binds surface-expressed 2D5A * 005 and 2DL5B * 003 did not bind to PVR.

[0163] Reciprocal responses between NK cells and dendritic cells (DCs) by cytokines or direct cell contact stimulation lead to activation and cytokine production by both cell types, contributing to the regulation of innate and adaptive immune responses (Cooper 2004; Walzer 2005). The present technology shows that KIR2DL5 can significantly reduce NK cell production of a wide range of cytokines and chemokines, such as IFN-γ, TNF-α, and GM-CSF, and subsequently impair NK cell-induced DC maturation and activation. PVR is highly expressed not only on tumor cells but also on several immune cell subsets, including DCs. TIGIT induces PVR phosphorylation and signaling in DCs, leading to increased IL-10 and decreased IL-12 production by DCs (Yu 2009). IL-12 released by DCs induces IFN-γ production and enhances NK cell cytotoxicity (Biron 1999).

[0164] ITIM and ITSM sequences found in many inhibitory receptors are crucial in transmitting negative signals through tyrosine phosphorylation and recruitment of phosphatases such as SHP-1 or SHP-2 (Daeron 2008; Long 2008). The tyrosine mutation studies herein revealed that both ITIM and ITSM are essential for KIR2DL5-mediated NK cell inhibition. KIR2DL5 recruited SHP-1 and SHP-2 in primary human NK cells. Notably, both phosphorylated ITIM and ITSM contributed to the association of KIR2DL5 with SHP-1. The association of KIR2DL5 with SHP-2 was entirely dependent on phosphorylated ITIM and not ITSM. ITIM / SHP-1 / SHP-2 and ITSM / SHP-1 inhibited Vav1 / ERK1 / 2 / p90RSK and downstream NF-κB signaling pathways. These findings reveal the molecular basis for KIR2DL5-mediated suppression on NK cells.

[0165] Preclinical studies have shown that the TIGIT / PVR axis is involved in CD8 +Due to its role in regulating T cell and NK cell responses, TIGIT has shown to be an attractive cancer immunotherapy target (Andrews 2019; Yu 2009; Stanietsky 2009). However, TIGIT blockade alone has shown minimal effects on tumor growth. While dual blockade of TIGIT and PD-1 / PD-L1 has shown promising results in several tumor models (Hung 2018; Johnston 2014; Dixon 2018) and multiple clinical trials (Bendell 2020; Niu 2022; Cohen 2021; Wainberg 2021; Rodriguez-Abreu 2020), the combination of the anti-TIGIT antibody tiragolumab and the PD-L1 inhibitor atezolizumab failed to improve progression-free survival in a phase III extensive-stage small cell lung cancer trial (ClinicalTrials.gov NCT04256421).

[0166] As disclosed herein, the non-competitive binding of KIR2DL5 and TIGIT to PVR suggested that both receptors can function simultaneously and independently, and that blocking the TIGIT / PVR axis leaves the KIR2DL5 / PVR pathway intact. Blockade of TIGIT had little effect on NK cytotoxicity, whereas blockade of KIR2DL5 significantly restored the cytolytic activity of NK cells. Thus, the presence of KIR2DL5-mediated inhibition of NK cells in the TME is a major obstacle to the success of TIGIT blockade. KIR2DL5 + Immune cells infiltrated a variety of human cancers that highly express PVR, and blockade of KIR2DL5 effectively inhibited tumor growth and improved mouse survival in multiple humanized mouse models.

[0167] Collectively, the findings disclosed herein elucidate the cellular and molecular mechanisms underlying the inhibitory function of the KIR2DL5 / PVR pathway and support blockade of the immunosuppressive KIR2DL5 / PVR axis, alone or in combination with other therapies, as a novel therapeutic strategy.

[0168] References 1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205-214. 2. Topalian SL, et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461. 3. Sharma P, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707-723. 4. Jenkins RW, et al. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9-16. 5. Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503-510. 6. Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015;6:266. 7. Romee R, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123. 8. Liu E, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-553. 9. Raulet DH, et al. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291-330. 10. Long EO, et al. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227-258. 11. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495-502. 12. Cozar B, et al. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11(1):34-44. 13. Andrews LP, et al. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425-1434. 14. Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85-100. 15. Wagtmann N, et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity. 1995;2(5):439-449. 16. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-251. 17. Winter CC, et al. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998;161(2):571-577. 18. Frazier WR, et al. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand. J Immunol. 2013;190(12):6198-6208. 19. Vilches C, et al. KIR2DL5, a novel killer-cell receptor with a D0-D2 configuration of Ig-like domains. J Immunol. 2000;164(11):5797-5804. 20. Cisneros E, et al. Allelic polymorphism determines surface expression or intracellular retention of the human NK cell receptor KIR2DL5A (CD158f). Front Immunol. 2016;7:698. 21. Gomez-Lozano N, et al. Some human KIR haplotypes contain two KIR2DL5 genes: KIR2DL5A and KIR2DL5B. Immunogenetics. 2002;54(5):314-319. 22. Du Z, et al. KIR2DL5 alleles mark certain combination of activating KIR genes. Genes Immun. 2008;9(5):470-480. 23. Verschueren E, et al. The immunoglobulin superfamily receptome defines cancer-relevant networks associated with clinical outcome. Cell. 2020;182(2):329-344. 24. Husain B, et al. A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3 / CD276 and PVR / CD155. Mol Cell Proteomics. 2019;18(11):2310-2323. 25. Shilts J, et al. A physical wiring diagram for the human immune system. Nature. 2022;608(7922):397-404. 26. Takai Y, et al. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9(8):603-615. 27. Kucan Brlic P, et al. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16(1):40-52. 28. Triki H, et al. CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration. Life Sci. 2019;231:116543. 29. Carlsten M, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67(3):1317-1325. 30. Castriconi R, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 2004;64(24):9180-9184. 31. Masson D, et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut. 2001;49(2):236-240. 32. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557-567. 33. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48-57. 34. Chan CJ, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15(5):431-438. 35. Bendell JC, et al. Phase Ia / Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors. Cancer Res. 2020;80(16):CT302. 36. Niu J, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer (NSCLC). Ann Oncol. 2022;33(2):169-180. 37. Cohen E, et al. SKYSCRAPER-09: a phase II, randomised, double-blinded study of atezolizumab (Atezo) plus tiragolumab (Tira) and atezo plus placebo as first-line (1L) therapy for recurrent / metastatic (R / M) PD-L1+squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol. 2021;32:814-815. 38. Wainberg Z, et al. Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Ann Oncol. 2021;32:227-228. 39. Rodriguez-Abreu D, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38(15):9503. 40. Ge Z, et al. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895. 41. Estefania E, et al. Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J Immunol. 2007;178(7):4402-4410. 42. Cisneros E, et al. KIR2DL5: an orphan inhibitory receptor displaying complex patterns of polymorphism and expression. Front Immunol. 2012;3:289. 43. Robinson J, et al. IPD-the Immuno Polymorphism Database. Nucleic Acids Res. 2010;38(D1):863-869. 44. Moretta L. Dissecting CD56dim human NK cells. Blood. 2010;116(19):3689-3691. 45. Lopez-Verges S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116(19):3865-3874. 46. Wu Y, et al. Developmental and functional control of natural killer cells by cytokines. Front Immunol. 2017;8:930. 47. Zang X. New immune checkpoint pathways: HHLA2 and its receptors including TMIGD2. Paper presented at: Cold Spring Harbor Asia Conference on Precision Cancer Biology: From Targeted to Immune Therapies; September 18-22, 2022; Suzhou, China. http: / / cshl.csh-asia.org / 2017meetings / CANCER.html. Accessed September 26, 2022. 48. Wei Y, et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021;6(61):eabf9792. 49. Bhatt RS, et al. KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1. Cancer Immunol Res. 2021; 9(2):156-169. 50. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol. 2008;8(9):713-725. 51. Treanor B, et al. Microclusters of inhibitory killer immunoglobulin-like receptor signaling at natural killer cell immunological synapses. J Cell Biol. 2006;174(1):153-161. 52. Daeron M, et al. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev. 2008;224:11-43. 53. Huyer G, et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem. 1997;272(2):843-851. 54. Yusa S, et al. KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol. 2004;172(12):7385-7392. 55. Pende D, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol. 2019;10:1179. 56. Carr WH, et al. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol. 2005;175(8):5222-5229. 57. Campbell KS, Purdy AK. Structure / function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132(3):315-325. 58. Cooper MA, et al. NK cell and DC interactions. Trends Immunol. 2004;25(1):47-52. 59. Walzer T, et al. Natural-killer cells and dendritic cells: “l’union fait la force”. Blood. 2005;106(7):2252-2258. 60. Biron CA, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220. 61. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev. 2008;224:70-84. 62. Stanietsky N, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(42):17858-17863. 63. Hung AL, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7(8):e1466769. 64. Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923-937. 65. Dixon KO, et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. 2018;200(8):3000-3007. 66. Zhao RH, et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A. 2013;110(24):9879-9884. 67. Doench JG, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184-191. 68. Wang F, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22-2 9. 69. Beziat et al. Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology. Immunology 150(3):248-264 (2016). 70. Wojtowicz et al. A human IgF cell-surface interactome reveals a complex network of protein-protein interactions. Cell 182(4):1027-1043 (2020). 71. Yu et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10(1):48-57 (2009).

Claims

1. 20. A method of increasing immune cell function in a subject, comprising administering to the subject one or more agents that decrease the expression and / or activity of KIR2DL5.

2. SUMMARY OF THE DISCLOSURE A method of treating an infectious disease in a subject in need thereof, comprising administering to the subject one or more agents that reduce the expression and / or activity of KIR2DL5.

3. A method of treating cancer in a subject in need thereof comprising administering one or more agents that reduce the expression and / or activity of KIR2DL5.

4. The method of any one of claims 1 to 3, wherein the one or more agents block or reduce binding of KIR2DL5 to the poliovirus receptor (PVR).

5. The method of claim 4 , wherein the one or more agents bind to KIR2DL5 at or near its binding site with PVR.

6. The method of claim 4 , wherein the one or more agents bind to PVR at or near the binding site for KIR2DL5.

7. The method of claim 6, wherein the binding of the one or more agents to PVR does not block the binding of PVR to TIGIT, DNAM-1 and CD96.

8. The method of any one of claims 1 to 7, wherein the one or more agents are selected from a peptide, a polypeptide or a small molecule.

9. The method of claim 8 , wherein the polypeptide is an antibody or a fusion protein comprising the antibody.

10. The method of claim 8 , wherein the antibody is a monoclonal antibody.

11. The method of claim 9 or 10, wherein the antibody is an antagonist antibody.

12. The method according to any one of claims 9 to 11, wherein the antibody or the fusion protein comprising the antibody comprises a high chain variable region (VH) comprising an amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, or SEQ ID NO:

30.

13. The method according to any one of claims 9 to 11, wherein the antibody or a fusion protein comprising the antibody comprises a VH region comprising an amino acid sequence encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, or SEQ ID NO:

30.

14. The method according to any one of claims 9 to 13, wherein the antibody or a fusion protein comprising the antibody comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27 or SEQ ID NO:

31.

15. The method of any one of claims 9 to 13, wherein the antibody or a fusion protein comprising the antibody comprises a VH region comprising an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27, or SEQ ID NO:

31.

16. The method according to any one of claims 9 to 15, wherein the antibody or a fusion protein comprising the antibody comprises a light chain variable region (LH) comprising an amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, or SEQ ID NO:

32.

17. The method according to any one of claims 9 to 15, wherein the antibody or a fusion protein comprising the antibody comprises an LH region comprising an amino acid sequence encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, or SEQ ID NO:

32.

18. The method according to any one of claims 9 to 17, wherein the antibody or a fusion protein comprising the antibody comprises an LH region comprising the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29 or SEQ ID NO:

33.

19. The method according to any one of claims 9 to 17, wherein the antibody or a fusion protein comprising the antibody comprises an LH region comprising an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29 or SEQ ID NO:

33.

20. The method according to any one of claims 9 to 19, wherein the antibody is a chimeric antibody, a human antibody or a humanized antibody.

21. The method according to any one of claims 2 to 20, wherein the infectious disease is caused by a pathogen.

22. 22. The method of claim 21, wherein the pathogen is selected from a virus, a bacterium, a prion, a fungus, a parasite, or a combination thereof.

23. 23. The method of claim 22, wherein the virus is selected from the group consisting of human immunodeficiency virus, influenza virus, papilloma virus, coronavirus, hepatitis virus and herpes virus.

24. 23. The method of claim 22, wherein the bacterium is Mycobacterium tuberculosis.

25. 23. The method of claim 22, wherein the fungus is Pneumocystis jirovecii (PJP).

26. The cancers include chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), T-cell lymphoma, B-cell lymphoma, T-cell acute lymphocytic leukemia (T-ALL), chronic myeloid leukemia (CML), B-cell prolymphocytic leukemia, T-cell lymphoma, Hodgkin's disease, B-cell non-Hodgkin's lymphoma, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, 15. The method of any one of claims 3 to 14, wherein the cancer is selected from the group consisting of hairy cell leukemia, small cell follicular lymphoma, large cell follicular lymphoma, malignant lymphoproliferative conditions, mucosa-associated lymphoid tissue (MALT) lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia or preleukemia.

27. 21. The method of any one of claims 3 to 20, wherein the cancer is selected from the group consisting of colon cancer, rectal cancer, renal cell carcinoma, liver cancer, lung cancer, kidney cancer, stomach cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulva cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, childhood solid tumors, bladder cancer, cancer of the kidney or ureter, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal tumors, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, environmentally induced cancer, combinations of cancers, and metastatic lesions of cancer.

28. The method of any one of claims 3 to 20, wherein the cancer is a human hematological malignancy.

29. The human hematological malignancies include myeloid neoplasms, acute myeloid leukemia (AML), AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML, acute leukemia of unclear lineage, myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, myelofibrosis (MF), primary myelofibrosis, systemic mastocytosis, myelodysplastic syndromes (MDS), myeloproliferative / myelodysplastic syndromes, chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, myelodysplastic syndromes (MDS), refractory anemia with sideroblasts, refractory cytopenia with polycythemia vera, refractory anemia with excess blasts (type 1), refractory anemia with excess blasts (type 2), MDS with isolated 5q deletion, unclassifiable MDS, myeloproliferative / myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myelogenous leukemia, juvenile myelomonocytic leukemia, unclassifiable myeloproliferative / myelodysplastic syndrome , lymphoid neoplasms, precursor lymphoid neoplasms, B lymphoblastic leukemia, B lymphoblastic lymphoma, T lymphoblastic leukemia, T lymphoblastic lymphoma, mature B cell neoplasms, diffuse large B cell lymphoma, primary central nervous system lymphoma, primary mediastinal B cell lymphoma, Burkitt lymphoma / leukemia, follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Walden 29. The method of claim 28, wherein the tumor is selected from Ström's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, post-transplant lymphoproliferative disorder, HIV-associated lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, primary cutaneous B-cell lymphoma, hairy cell leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, or solitary plasmacytoma (bone and extramedullary).

30. The method according to any one of claims 3 to 20, wherein the cancer is selected from the group consisting of bladder cancer, kidney cancer, breast cancer, lung cancer, liver cancer, brain cancer, prostate cancer, colon cancer, esophageal cancer, pancreatic cancer, uterine cancer and gastric cancer.

31. The method of any one of claims 3 to 20, wherein the cancer is a metastatic cancer.

32. The method of any one of claims 3 to 20, further comprising administering to the subject one or more additional cancer treatments selected from chemotherapy, radiation therapy, immunotherapy, surgery, and combinations thereof.

33. 20. A method of decreasing immune cell function in a subject, comprising administering to the subject one or more agents that increase expression and / or activity of KIR2DL5.

34. SUMMARY OF THE DISCLOSURE A method of treating an autoimmune disease in a subject, comprising administering to the subject one or more agents that increase expression and / or activity of KIR2DL5.

35. 20. A method of reducing transplant rejection in a subject, comprising administering to said subject one or more agents that increase expression and / or activity of KIR2DL5.

36. The method of any one of claims 33 to 35, wherein the one or more agents are selected from the group consisting of peptides, polypeptides and small molecules.

37. 37. The method of claim 36, wherein the polypeptide is a fusion protein or an antibody.

38. 38. The method of claim 37, wherein the antibody is a monoclonal antibody.

39. 39. The method of claim 37 or 38, wherein the antibody is an agonistic antibody.

40. The method of claim 39 , wherein the antibody increases the activity of KIR2DL5.

41. The method according to any one of claims 37 to 40, wherein the antibody is a chimeric antibody, a human antibody or a humanized antibody.

42. The autoimmune disease includes acute disseminated encephalomyelitis (ADEM), alopecia areata, antiphospholipid syndrome, autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disorder, autoimmune lipoproliferative syndrome, autoimmune peripheral neuropathy, autoimmune pancreatitis, autoimmune polyendocrine syndrome, autoimmune progesterone dermatitis, autoimmune thrombocytopenic purpura, autoimmune urticaria, autoimmune uveitis, Behcet's disease, celiac disease, Chagas disease, cold agglutinin disease, Crohn's disease, dermatomyositis, type 1 diabetes, eosinophilic fasciitis, digestive tract infections, and the like.

42. The method of any one of claims 34 to 41, wherein the disease is selected from the group consisting of pulmonary pemphigoid, Goodpasture's syndrome, Graves' syndrome, Guillain-Barre syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, lupus erythematosus, Miller Fisher syndrome, mixed connective tissue disease, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polymyositis, psoriasis, psoriatic arthritis, relapsing polychondritis, rheumatoid arthritis, rheumatic fever, Sjogren's syndrome, temporal arteritis, transverse myelitis, ulcerative colitis, undifferentiated connective tissue disease, vasculitis, Wegener's granulomatosis, and adult rheumatoid arthritis.

43. The method of any one of claims 35 to 41, wherein the transplant is a stem cell transplant, a bone marrow transplant, or a combination thereof.

44. The method of any one of claims 35 to 41, wherein the transplant is selected from the group consisting of a kidney transplant, a lung transplant, a heart transplant, a pancreas transplant, a cornea transplant or a liver transplant.

Citation Information

Patent Citations

  • Methods and compositions for increasing efficacy of therapeutic antibodies using nk cell enhancing compounds

    JP2006528626A

  • Method for treating cancer patients using a farnesyl transferase inhibitor

    JP2018519264A

  • Cell for resisting transplant reaction and method

    WO2020259707A1